COMPOSITIONS AND METHODS FOR WOUND HEALING

Abstract: Mice in which enhanced wound healing occurs can be used to identify genes and gene products which are involved in enhanced wound healing in mammals, including humans. Methods and compositions for treating wounds, including central and peripheral nerve wounds, are also provided.

Description: COMPOSITIONS AND METHODS FOR WOUND HEALING This application claims the benefit of co-pending provisional applications Serial No. 60/074,737 filed February 13, 1998, Serial No. 60/097,937 filed August 26, 1998, and Serial No. 60/102,051 filed September 28, 1998, which are incorporated herein by reference. This work was partially supported by the U.S. Government under USPHS grant AI42395 awarded by the National Institutes of Health. The U.S. Government retains certain rights in this invention. TECHNICAL FIELD OF THE INVENTION This invention is related to the field of wound healing. More particularly, the invention is related to methods and compositions for enhancing wound healing in mammals. BACKGROUND OF THE INVENTION The biological response to tissue injury in higher organisms falls into two main categories: wound repair and regeneration (1). In amphibians, the form of wound healing seen is often epimorphic regeneration, where entire limbs can be reformed after amputation (1). In adult mammals, wound healing can involve wound repair or tissue regeneration, including the replacement of mature cells through cell proliferation (7) or replenishment of cells, but not organs, from immature stem cells (9, 11, 25). Complete wound healing, however, with perfect replacement of tissue and function, is typically not observed. Injuries to the central and peripheral nervous system, including optic nerve and spinal cord injuries, are especially refractory to healing. Thus, there is a need in the art for methods and compositions for enhancing wound healing in mammals. SUMMARY OF THE INVENTION It is an object of the invention to provide methods and compositions for use in healing wounds. These and other objects of the invention are provided by one or more of the embodiments described below. One embodiment of the invention is a method of identifying a gene involved in enhanced wound healing. DNA microsatellite markers which can distinguish a first and a second mouse strain are identified. The first mouse strain is a healer mouse strain, and the second mouse strain is not a healer mouse strain. Microsatellite markers which segregate with enhanced wound healing in progeny of the first and second mouse strains are identified. A chromosomal locus which contains at least one gene involved in enhanced wound healing is thereby identified. Still another embodiment of the invention is a method of treating a wound in a mammal. A reagent which specifically binds to an expression product of a gene whose expression is decreased in a healer mouse relative to a non-healer mouse is administered to a mammal with a wound. Expression of the gene is thereby decreased. Even another embodiment of the invention is a method of treating a wound in a mammal. An expression product of a gene whose expression is increased after wounding in a healer mouse relative to expression of the gene after wounding in a non-healer mouse is administered to a mammal with a wound. The level of the expression product in the wound is thereby increased. Yet another embodiment of the invention is a method of restoring function after nerve injury in a mammal. A reagent which specifically binds to an expression product of a gene whose expression is decreased after wounding in a healer mouse relative to expression of the gene after wounding in a non-healer mouse is administered to a mammal with a nerve injury. Expression of the gene is thereby decreased. Another embodiment of the invention is a method of restoring function after nerve injury in a mammal. An expression product of a gene whose expression is increased after wounding in a healer mouse relative to expression of the gene after wounding in a non-healer mouse is administered to a mammal with a nerve injury. The level of the expression product in the wound is thereby increased. Still another embodiment of the invention is a method of treating a wound in a mammal. A cell or cellular extract obtained from a healer mouse is administered to a mammal with a wound. Healing of the wound in the mammal is thereby enhanced. Yet another embodiment of the invention is a method of treating a wound in a mammal. A cell in which expression of a wound healing gene has been altered is administered to a mammal with a wound. Healing of the wound in the mammal is thereby enhanced. Even another embodiment of the invention is a healer mouse having at least one quantitative trait locus selected from the group consisting of the quantitative trait loci shown in Tables 2, 9 and 16. The healer mouse exhibits an enhanced healing response to a wound compared to a mouse which does not have the at least one chromosomal locus. The healer mouse is not an MRL mouse. Yet another embodiment of the invention is a preparation comprising a fraction of an extract of a tissue of a healer mouse. The preparation alters a biological property of a model of wound healing. Still another embodiment of the invention is a preparation comprising cells of a healer mouse. The preparation alters a biological property of a model of wound healing. Another embodiment of the invention is a method of identifying a factor involved in enhanced wound healing. A model of wound healing is contacted with a preparation selected from the group consisting of serum, a fraction of serum, an extract of at least one healer mouse tissue, and a fraction of an extract of at least one healer mouse tissue. A property of the model of wound healing is assayed. A preparation which alters the property of the model of wound healing is identified as comprising a factor involved in enhanced wound healing. Yet another embodiment of the invention is a method of screening test compounds for the ability to enhance wound healing. A healer model of wound healing is contacted with a test compound. The healer model comprises cells of a healer mouse. The effect of the test compound on a biological property associated with wound healing is measured in the healer model. A test compound which enhances the biological property of the healer model is identified as a potential factor for enhancing wound healing. The present invention thus provides the art with a mammalian model of enhanced wound healing. The healer mouse described herein can be used, inter alia, to identify genes and gene products involved in enhanced wound healing and to provide methods and compositions for healing wounds, particularly wounds of the nervous system, in mammals. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1. The kinetics of ear punch hole closure. Two mm holes were punched in ears on day 0 and, for each strain of mouse, holes were measured at days indicated on the horizontal axis. Average hole diameters are shown (n=4). Figure 2. Photographs of the healing ear wounds. C57BL/6 (left side) and MRL/lpr (right side) ears were punched bilaterally in the center of the ears creating a 2 mm through-and-through wound and followed for 33 days. The ear holes of the C57BL/6 mouse remained open 1 day (Figure 2A), 9 days (Figure 2B), 20 days (Figure 2C), and 33 days (Figure 2D) after punching. In the MRL/lpr mouse, one can see the progression of hole closure from day 1 (Figure 2E), day 9 (Figure 2F), day 20 (Figure 2G), to day 33 (Figure 2H). Figure 3. Histological examination of early events in ear hole closure. The first two days after wounding of C57BL/6 ears (Figures 3A and 3D) and MRL/+ (Figures 3B and 3E) and MRL/lpr ears (Figures 3C and 3F) were examined. Day 1 : these sections show more swelling at the wound site for the MRL tissue (smaller arrows). Eschar and inflammatory cellular infiltrate at the wound margin is similar for both strains and re-epithelialization is not seen (larger arrows). Day 2: The C57BL/6 wound is partially covered (arrow) by eschar with migrating epithelium not yet covering the wound (9 out of 14 edges examined did not close) while the MRL wound is completely covered (arrows) with epithelium (10 out of 14 edges examined completely closed). Magnification = 40x; tissue is stained with hematoxylin and eosin. Figure 4. Day 5, 10, and 20 wounds. For all days indicated for C57BL/6 tissue (A), MRL/+ tissue (B) and MRL/lpr tissue (C). All sections are stained with hematoxylin and eosin (pictures are representative of 4 edges examined). Figure 4 A. Day 5 (A, B, C: 40x-upper panels and 20x-lower panels): Swelling at the MRL wound site is extensive with neovascularization (40x-arrows) and marked dermal fibroblast proliferation (20x-large arrows). Adnexae in the new epithelium can be seen here (20x-small arrows). A C57BL/6 wound that has failed to epithelialize is shown here, although this is not typical (20x- *). Figure 4B. Day 10 (A, B, C: 40x-upper panels and 1 Ox-lower panels): There is marked neovascularization (40x-arrows) and fibroblast proliferation (1 Ox-arrows) seen in the MRL wound extending out beyond the borders of the wound where the cut cartilage edges are seen. Note the extent to which dermal cells have migrated out beyond the wound margin marked by the cartilage edge for the two MRL ears compared to the C57BL/6 ear. Figure 4C. Day 20 (A, C:20x; B:40x-upper panels and 5x-lower panels): The prominent proliferation of fibroblasts in the dermis and the appearance of a blastema-like structure has led to significant closure of the MRL wound as originally marked by the cut edges of cartilage at the right and left margins of the photograph (5x-between arrows). By comparison, there is little extension of C57BL/6 tissue into the wound space. The homogeneity of fibroblast proliferation and ECM deposition is most striking in MRL (B:40x-upper panel). Figure 5. Late-stage ear wound closure. Wound sites (n=3) 81 days after wounding for C57BL/6 (top) and MRL/lpr (bottom) mice were aligned using a dissection microscope and sutured together to assure sectioning through the former wound for MRL/lpr tissue. Cartilagenous islands (small arrow) present throughout the MRL/lpr section are surrounded by prominent adipocytes (large arrow). These features are absent from the C57BL/6 tissue. The tissue sections are stained with Gomori trichrome. Magnification = lOx. Figure 6. The analysis of frequencies of wound closure on day 30 in parental and crossbred populations. Histograms of day 30 ear punch hole diameters can be seen for the following genotypes: C57BL/6 and MRL/lpr parental mice and F, mice (upper panel) and the first backcross to each parental strain (lower panel). Figure 7. Histogram of wound closure in (MRL/lpr x C57BL/6)F, and F 2 intercross populations. Figure 8. Additive effects of heall and heal3 on wound closure. Average residual wound diameters are plotted for each genotype, with the results grouped by D13Mitl29 and D8Mit211. The mean of all F 2 mice ± 1 s.e.m. is depicted as a horizontal line in this graph. B, H, and S designate mice homozygous for the heal b b allele from C57BL/6, heterozygous for the heal b s alleles from C57BL/6 and MRL/lpr, or homozygous for the heal ^ allele from MRL/lpr, respectively. Figure 9. Healer and non-healer mice 1.5 months after transection of the left optic nerve. Figure 9A. The non-healer (B6) mouse exhibits complete atrophy of the left eye with marked sinking of the left eye socket compared to the normal untreated right eye. Figure 9B. The healer (MRL) mouse exhibits only slight sinking of the left eye compared to the normal, untreated right eye. Figure 10. Images depicting histological longitudinal sections of the healer (MRL) mouse uncut right eye-specific tissue. These serial sections were stained with hematoxylin and eosin. Figure 11. A series of images depicting histological longitudinal sections of the healer (MRL) mouse cut left eye-specific tissue. These serial sections were stained with hematoxylin and eosin. Figure 12. Figure 12A is an image depicting a histological longitudinal section of the healer (MRL) mouse normal uncut right eye-specific tissue. This section was stained with Bodian's silver stain specific for axons. Figure 12B is an image depicting a histological longitudinal section of the healer (MRL) mouse cut left eye-specific tissue. This section was stained with Bodian's silver stain specific for axons. The blue arrows indicate nerve fibers and the red arrows point to oligodendrocytes. Figure 13. Graph depicting nerve regeneration in various strains of mice. SFI, Sensory Function Index. Figure 14. Graph depicting healing of ear holes in LG mice. Figure 15. Graph depicting adoptive transfer of the healing ability of MRL mice, wherein macrophages obtained from healer mice were transferred to non- healer mice. Figure 16. Results from microarray analysis of gene expression in MRL mice after ear punch. Series 1, no ear punch; Series 2, 24 hours after ear punch; Series 3, 40 hours after ear punch. Names of genes are given in Table 11. Figure 17. Graph showing the effect of age on the time course of ear hole closure in healer mice. Figure 18. Graph demonstrating that T cell depletion leads to complete healing in aged healer mice. Figure 19. Bar graph demonstrating that T cell receptor knock-outs show enhanced healing. Figure 20. Bar graph showing that adoptive transfer of fetal liver into X- irradiated non-healer recipients enhances wound healing. Figure 21. Two-day old explant cultures of punched ears of healer and non- healer mice. Figure 21A, explant of a healer mouse ear punch. Figure 21B, magnified view of the healer mouse ear punch explant. Figure 21C, explant of a non-healer mouse ear punch. Figure 21D, magnified view of the non-healer ear punch explant. Figure 22. Magnified view of the area around a healer mouse ear punch explant. demonstrating migration of cells away from the explant. Figure 23. Graph demonstrating that adoptive transfer of bone marrow- derived dendritic cells into ear-punched C57BL/6 Rag ' ' " immunodeficient mice enhances wound healing. DETAILED DESCRIPTION It is a discovery of the present invention that healer mice, including MRL mice and strains derived from MRL mice, can be used as murine models of wound healing, particularly of the central and peripheral nervous system. These models are useful for identifying genes and gene products which are involved in enhanced wound healing in mammals, including humans, as well as for developing therapeutic compounds and methods to enhance wound healing. Healer Mice Typically, holes punched in the ears of non-healer mice are permanent and exhibit at most about 25% closure even 60 days after punching. Patterns of such holes can thus be used to distinguish individual non-healer mice from one another, which is a standard laboratory method for animal identification. In contrast, a hole punched in the ear of a healer mouse will close at least 70%, more preferably at least 80% or 90%, within 60 days, more preferably within 45 or 30 days. Most preferably, an ear hole of a healer mouse closes completely. The percent closure of a hole punched in the ear of a mouse can be determined by measuring the initial diameter of the hole and by taking subsequent measurements during the first thirty days after punching. Typically, a 2 mm hole is punched. In particularly preferred healer mouse strains, complete ear hole closure occurs 30 days after punching, without scar tissue and with regeneration (perfect replacement) of cell types initially present in the ear, such as cartilage, dermis, epidermis, and blood vessels. The healing capacity of a mouse strain can easily be tested by an ear punch assay, as described above. However, healing capacity can be assessed following other types of wounds in the mouse, including, but not limited to, digit cutting, tail cutting, and cutting or crushing of a nerve, particularly an optic or sciatic nerve, or a partial or complete cutting or crushing of the spinal cord. Liver regeneration can also be measured. In addition to ear hole closure as described above, a mouse strain with a healer phenotype, in contrast to a non-healer mouse, may also exhibit one or more of the following characteristics. All such aspects of the healer phenotype, including enhanced tissue regeneration, are components of enhanced wound healing. Blastemas may form in the vicinity of a cut in the ear, digits, tail, or liver in a strain of healer mouse. Following injury to the liver, a strain of healer mouse may exhibit rapid replacement of liver mass and homeostasis. A healer mouse strain may exhibit breakdown in the extracellular matrix-basement membrane to allow epithelial- mesodermal interaction and may express forms of extracellular matrix-basement membrane components, such as tenascin, which are typically expressed only during development or regeneration. Organ regeneration can also occur. Healer mouse strains may also exhibit rapid recovery from central or peripheral nerve damage, such as sciatic or optic nerve crush, or cutting or crushing of the spinal cord, and can thus be used as models in which to study regeneration of injured nerves. Nerve regeneration can be detected using functional assays appropriate for the particular nerve involved, such as electrical stimulation of the nerve and detection of contraction of the reinnervated muscle, or can be detected by observing restoration of normal neuronal architecture as a precursor to reacquisition of complete or partial normal function. In preferred healer mouse strains, regrowth and connection occurs after complete transection of nerves of the central or peripheral nervous system. Most preferably, healer mice exhibit maintenance of the optic nerve and eye with no accompanying degeneration of either structure following injury, such as crushing or transection, of the optic nerve. In addition, neurites regrow in the proper direction through a cut region of the optic nerve, and glial cells, such as oligodendrocytes, reappear in the injured area. After cutting or crushing of the spinal cord at the thoracic level, for example, preferred strains of healer mice recover at least partial function in their hind limbs and tail. Healer mouse strains can be naturally occurring or can be generated, for example, by traditional genetic crossings, by transgenic manipulation, or by mutagenic techniques, as is known in the art. One strain of healer mouse is the MRL mouse. The MRL mouse (H-2k) is derived from an interbreeding of the LG mouse (75%; H-2d/f), the AKR mouse (12.6%; H-2k); the C3H mouse (12.1% h-2k) and the C57B1/6 mouse (0.3%; H-2b) (13) and was selected originally for its large size. A mutant derived from this colony, MRL/lpr showed enlarged spleen and lymph nodes with age, lymphoproliferation with aberrant control of apoptosis in germinal centers, and a high susceptibility to autoimmune disease with autoantibodies, an arthritis-like syndrome, and glomerulonephritis. This was shown to be the direct result of a retrotransposon insertion into the second intron of the fas gene in the lpr strain (16, 17, 23). However, the rapid and complete wound closure described here is unrelated to fas since the MRL/+ mouse has the same healing characteristics. Furthermore, wound closure is unlinked to the lympadenopathy (R=0.4) associated with lpr mice and the autoantibodies made to histone proteins by these animals (13-15, 24). This lack of fas involvement has been confirmed in mapping studies using MRL/lpr and C57BL/6 backcross mice showing a clear genetic basis for this regeneration trait, unlinked to the fas genetic locus (McBrearty etal., Proc. Natl. Acad. Sci. U.S.A. 95, 11792-97, 1998). One characteristic of the MRL mouse is its large size, but there is no evidence that this trait is linked to adult body weight (R=0.12). Other preferred strains of healer mice can be generated by crossing a healer mouse, such as an MRL mouse, with a non-healer mouse, such as a C57BL/6 mouse, and selecting progeny (F,) mice which display a healer phenotype. F, healer mice can be intercrossed to form an F 2 generation, in which mice with a healer phenotype can be identified. Alternatively, a male or female F, healer mouse can be back- crossed with a female or male mouse of its healer or non-healer parent strain. The progeny of any of these crosses which display a partial or a complete healer phenotype are healer mice according to the invention. Other non-healer mouse strains, such as 129, can be crossed with a non-healer strain such as C57BL/6 to form healer mouse strains. Characteristics of the healer phenotype are those which are described above. Mutagenic techniques, including but not limited to, targeted and non-targeted chemical mutagenesis using agents such as DMBA and ENU, as well as irradiation, for example with UV light or X-rays, can be used to induce mutations in one or more genes involved in enhanced wound healing to form a healer phenotype. Genes which can be mutated include, but are not limited to, the genes disclosed herein in Tables 4-11, 14, 15, and genes comprising the SAGE tags disclosed in Tables 12 and 13, as well as genes which regulate them. It is also possible to create healer mouse strains using transgenic manipulations, to create transgenic, knock-in, or knock-out mice in which the function of one or more genes involved in the enhanced healing response is altered to achieve a healer phenotype. The genes of Tables 4-11, 14, 15, and genes comprising the SAGE tags disclosed in Tables 12 and 13, as well as genes which regulate them, are candidates for such manipulation. Conditional knock-in or knockout mice, which will express one or more wound healing genes at a designated developmental stage or under particular environmental conditions, can also be constructed. Methods of creating transgenic, knock-in, and knock-out mice are well- known in the art. (See, e.g., U.S. Patents 5,464,764 and 4,873,191). Identification of Wound Healing Factors Healer mice can also be used to identify factors which promote wound healing, particularly recovery from central or peripheral nerve injury, as well as genes which encode the factors. Either in vitro or in vivo models of wound healing can be used for this purpose. In vitro models can comprise tissue explants or cells. For example, all or a portion of an ear comprising a cut or a punch wound can conveniently be maintained as an explant in a collagen gel. Explants of other tissues, such as skin and nerve tissue, can also be used. Methods of maintaining tissue explants are well known in the art. Mammalian cell lines or primary cultures of mammalian cells can also be used as in vitro models of wound healing. Suitable cell types include, but are not limited to, epidermal, mesodermal, cartilage, muscle, neuronal, glial, macrophage, and liver cells or cell lines. Many such cell lines can be obtained from commercial sources such as the American Type Culture Collection. Primary cells can be isolated from mammals such as mice, rabbits, rats, pigs, hamsters, monkeys, or humans. Methods of maintaining such cells in vitro as monolayers, suspension cultures, or cellular reaggregates are also well known. Alternatively, the model can be a mammal, such as a rat or mouse, which has a wound. The wound can be, for example, a cut or abrasion in the skin, a tail or ear cut or an ear punch, a cut in the liver, or a severed or crushed nerve, including an optic nerve or spinal cord. The effects of partially or fully purified proteins or nucleic acids, whole cells, such as macrophages or fibroblasts, or tissue extracts, including serum, obtained from healer mice can be tested in the in vitro or in vivo model of wound healing. Regeneration of the tissues and cells and/or morphological or biochemical changes associated with wound healing can be assessed and compared with those processes in the absence of added proteins, cells, or tissue extracts obtained from healer mice or in the presence of proteins, cells, or extracts obtained from non-healer mice. Cells such as fibroblasts, macrophages, and nerve cells isolated from healer and non-healer mice can be treated with cells, serum, or cell extracts from either non-healer or from healer mice. Properties of a wound healing model which can be assessed include, but are not limited to, enhanced wound healing, enhanced tissue regeneration, cell growth, apoptosis, cell replication, cell movement, cell adhesion, DNA synthesis, protein synthesis, mRNA synthesis, and mRNA stability. Methods of assessing these properties include moφhological assessment, either with or without the aid of a microscope, as well as biochemical and molecular biology methods well-known in the art. The alteration of at least one of these properties or of another property associated with enhanced wound healing or tissue regeneration, including an alteration in the time course of an effect, identifies a factor involved in these processes. Extracts can be prepared from tissues and cells of healer mice using standard tissue disruption techniques, such as sonication, passage through a French press, Dounce homogenization, blending, Polytron disruption, enzymatic digestion, or blending with glass beads, followed by centrifugation. If desired, an extract can be divided into one or more fractions to further identify particular factors involved in enhanced wound healing. Any known method of fractionation, including fractional precipitation with ammonium sulfate, polyethylene glycol, or organic solvents, gel permeation or gel filtration chromatography, ion exchange chromatography, hydrophobic chromatography, dye-ligand affinity chromatography, bio-ligand affinity chromatography, high performance liquid chromatography, fast-flow liquid chromatography, electrophoretic separation methods, and the like, can be used, as is convenient. Extracts or fractions of extracts which cause an alteration in an in vitro model or which enhance wound healing in an explant or an in vivo model can be purified by biochemical, molecular biological, and/or immunological means using standard technology or can be identified, for example, by selective inactivation. Methods such as two-dimensional gel electrophoresis can also be used to identify proteins which are present or absent, or which are present in different amounts in healer mice compared with non-healer mice. The effects of a purified factor can be confirmed using either an in vitro or an in vivo model of wound healing, as described above. Alternatively, a subtractive hybridization-type approach can be used to identify factors capable of enhancing wound healing or tissue can be obtained from healer mice, and mRNA can be extracted from these cells using methods well known in the art. Specific rnRNAs which are expressed in the cells of healer mice can be isolated by subtractive hybridization of healer mRNA with mRNA obtained from identical cells from non-healer mice. Differentially expressed mRNAs can then be reverse transcribed to form cDNA. Genes encoding such factors may then be identified, cloned, sequenced and otherwise characterized, as is known in the art. cDNA can be cloned into an expression vector using standard methodologies. Protein expressed from the cDNA can be tested for the ability to enhance wound healing or tissue regeneration of mammalian tissue in an in vitro or in vivo model such as those described above. cDNA which encodes a protein identified as involved in enhanced wound healing can be sequenced and further characterized as desired using ordinary molecular biology technology. The technology required to perform these experiments is well known in the art and is described, for example, in Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL (Cold Spring Harbor Laboratory, New York, 1989) and in Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Green & Wiley, New York, 1993). - Any murine wound healing factors which are identified using a healer mouse can be used to identify counteφart factors in other mammals, particularly in humans. For example, degenerate primers encoding portions of murine wound healing factors can be constructed and used to probe cDNA libraries of other mammalian species, preferably human cDNA libraries. Antibodies which specifically bind to a murine wound healing factor can be used to identify similar factors in cells, tissues, extracts, or expression libraries of other mammalian species, preferably human. Thus, the invention should be construed to include the identification of any and all mammalian wound healing factors which share homology with those identified in the murine systems described herein. The invention also provides methods of screening test compounds for the ability to enhance wound healing. The test compounds can be pharmacologic agents already known in the art or can be compounds previously unknown to have any pharmacological activity. The compounds can be naturally occurring or designed in the laboratory. They can be isolated from microorganisms, animals, or plants, and can be produced recombinantly, or synthesized by chemical methods known in the art. Members of combinatorial libraries can also be screened for wound healing activity. A healer model of wound healing is contacted with a test compound. The healer model comprises cells of a healer mouse, and can be any of the in vitro or in vivo types of wound healing models described above. Healer models in which healer and non-healer cells are mixed can also be used. The effect of the test compound on a biological property associated with wound healing is measured in the healer model. These biological properties include, but are not limited to, enhanced wound healing, enhanced tissue regeneration, cell growth, apoptosis, cell replication, cell movement, cell adhesion, DNA synthesis, protein synthesis, mRNA synthesis, and mRNA stability. A test compound which enhances the biological property of the healer model is identified as a potential factor for enhancing wound healing. Optionally, the effect of the test compound on the biological property of the healer model can be compared with its effect on the same or a similar biological property of a non-healer model of wound healing. Non-healer models are any of the in vitro or in vivo models described above, but do not comprise healer mouse cells. A test compound which alters the biological property of the non-healer model such that it resembles the biological property of the healer model is identified as a potential factor for enhancing wound healing. Identification of Healer Chromosomal Loci and Genes Healer mice are particularly useful for identifying genes which are differentially expressed in healer vs. non-healer mice and which are involved in enhanced wound healing. Wound healing genes include genes whose products are directly involved in enhanced wound healing or tissue regeneration, as well as genes which regulate them. Such genes can be identified by a variety of methods. For example, differentially expressed wound healing genes can be identified based on microarray, SAGE, and RT-PCR analyses, as described in the Examples, below. Chromosomal loci which contain at least one gene which encodes a protein involved in enhanced wound healing can be identified by genome screening. DNA microsatellite markers are identified which can distinguish two strains of mice. One of the two strains is a healer mouse strain, such as the MRL mouse or its progeny. The other strain is a non-healer mouse, such as a C57BL/6. A number of suitable mouse strains are available commercially, for example from Jackson or Taconic Laboratories. Microsatellite markers which segregate with enhanced wound healing in progeny of the two strains identify a chromosomal locus which contains at least one gene which is involved in enhanced wound healing. The product of this gene may be directly involved in enhanced wound healing or may regulate expression of another gene which is involved in enhanced wound healing. This method is described in detail in Examples 3-7, below. Certain quantitative trait loci identified by this method can be observed to segregate with either male or female healer mice. For example, the quantitative trait loci identified on chromosome 7 segregate with male mice, as do some of the quantitative trait loci on chromosome 13. In addition, quantitative trait loci identified on chromosomes 4 and 18 segregate with male mice. On the other hand, the quantitative trait loci identified on chromosomes 12 and 15 segregate with female mice. Congenic mouse strains, created by successive back-crossings of the F, generation of a healer x non-healer cross with its non-healer parent strain and selected for a healer phenotype, are especially useful for identifying chromosomal loci which segregate with the healer phenotype. The healer phenotype of such congenic healer mice ranges from mice with the ability to heal a 2 mm ear hole at least 75% to mice which heal such ear holes completely. For example, after six successive back-crossings, a healer mouse strain was identified which retains approximately 2% of the markers of the healer mouse genome, including the quantitative trait loci shown in Tables 2 , 9, and 16, and which exhibits a healer phenotype (Example 19 and Table 16). By repeated back-crossings, strains of healer mice can be created which have at least one of the quantitative trait loci shown in Tables 2 , 9, and 16. One locus of particular interest is marker 39, located at 29 cM on chromosome 16. This locus coincides with the location of a wound healing gene termed p63, located between 14 and 29 cM on chromosome 16. A number of genes involved in enhanced wound healing or tissue regeneration have been identified using these methods. Genes which are differentially expressed between healer and non-healer mouse dendritic cells are shown in Table 15. Genes whose expression is differentially increased or decreased in healer mice after wounding, such as ear punching, are shown in Tables 5, 6, 7, 8, 10, 11, and 15. Levels of some gene products, such as ezrin, c-Jun, and c-myc, are increased in both males and females. Levels of other gene products, such as PI-K p58, and glutathione s-transferase, are decreased in both males and females after wounding. Still other gene products show more complex changes after wounding, being altered only in males or females, at early or late stages after wounding, or a combination of both. For example, the hox8 (msx2) gene is over-expressed in healer mice at 0, 1, and 5 days after ear punch, but its expression decreases at about 20 days after ear punch, when the ear begins to heal. Therapeutic Methods for Treating Wounds Manipulation of the expression of wound healing genes in non-healer mammals, including altering effective levels of their expression products, in non- healer mammals can be used to treat wounds and to enhance or promote wound healing, particularly in humans. Wounds can be treated at early or late stages after wounding by selectively manipulating expression of particular wound healing genes. Certain of these genes are identified in Tables 5, 6, 7, 8, 10, 11, and 15. Optionally, expression of one or more wound healing genes can be manipulated simultaneously or sequentially. Furthermore, wounds in males or females can be treated most effectively by selecting the appropriate wound healing genes for manipulation. Expression of genes of Tables 5, 6, 7, 8, 10, 11, and 15 whose expression is selectively decreased and/or increased in healer mice at particular times after wounding can be manipulated in order to enhance wound healing. Particularly preferred genes are msx2 and RARg. Any method known in the art can be used to decrease or increase expression of a wound healing gene. Methods of decreasing effective expression of a wound healing gene include, but are not limited to, use of ribozyme, antisense, or antibody technologies. Methods of increasing effective expression of a wound healing gene include, but are not limited to, providing polynucleotide sequences encoding expression products of the gene such as protein or mRNA, as well as providing the expression products themselves. In one embodiment of the invention, expression of a wound healing gene is altered using an antisense oligonucleotide sequence. The antisense sequence is complementary to at least a portion of the coding sequence of the gene. The coding sequences of preferred wound healing genes can be obtained from databases such as Genbank; accession numbers for some of thtese genes are provided in Table 14. Preferably, the antisense oligonucleotide sequence is at least 11 nucleotides in length, but can be at least 12, 15, 20, 25, 30, 35, 40, 45, or 50 or more nucleotides long. Longer sequences can also be used. Antisense oligonucleotide molecules can be provided in a construct and introduced into cells using standard methodologies to decrease expression of one or more wound healing genes. Antibodies which specifically bind to a wound healing protein can also be used to alter the effective expression levels of a wound healing gene. Wound healing- specific antibodies bind to a wound healing protein and prevent the protein from functioning in the cell. Preparations of polyclonal and monoclonal antibodies can be made using standard methods. Antibody fragments such as Fab, single-chain Fv, or F(ab') 2 fragments can also be prepared. If desired, antibodies and antibody fragments can also be "humanized" in order to prevent a patient from mounting an immune response against the antibody when it is used therapeutically, as is known in the art. Other types of antibodies, such as chimeric antibodies, can be constructed as disclosed, for example, in WO 93/03151. Binding proteins which are derived from immunoglobulins and which are multivalent and multispecific, such as the "diabodies" described in WO 94/13804, can be prepared and used in methods of the invention. Anti-idiotype antibodies, directed against unique sequence variants in wound healing gene products, can also be used in therapeutic methods of the invention. Useful antibodies specifically bind to epitopes present in proteins encoded by a wound healing gene. The amino acid sequences of these proteins are available from Genbank (see, e.g., Table 14 for accession numbers). Antibodies which specifically bind to wound healing proteins provide a detection signal at least 5-, 10-, or 20-fold higher than a detection signal provided with other proteins when used in Western blots or other immunochemical assays. Preferably, antibodies which specifically bind to a wound healing protein do not detect other proteins in immunochemical assays and can immunoprecipitate the wound healing protein from solution. Antibodies can be purified by methods well known in the art. For example, the antibodies are affinity purified, by passing the antibodies over a column to which a wound healing protein is bound. The bound antibodies can then be eluted from the column, for example, using a buffer with a high salt concentration. Ribozymes can be used to inhibit gene function by hybridizing to and cleaving an RNA sequence of a wound healing mRNA, as is known in the art (e.g., Haseloff et al., U.S. Patent 5,641,673). The nucleotide sequences of wound healing genes, available from databases such as Genbank (see Table 14), are sources of suitable hybridization region sequences. Preferably, the mechanism used to decrease the effective expression of the involved gene decreases levels of gene expression products, such as mRNA or protein, by 50%, 60%, 70%, or 80%. Most preferably, effective expression of the gene is decreased by 90%, 95%, 99%, or 100%. Effective expression of the involved gene can be assessed using methods well known in the art, such as hybridization of nucleotide probes to mRNA of a wound healing gene, quantitative RT-PCR, or detection of wound healing protein using specific antibodies. Expression of wound healing genes whose expression is increased in healer mice after wounding can be effectively increased in a non-healer mammal in order to enhance wound healing. Any method known in the art for enhancing gene expression can be used for this puφose. For example, the coding sequence of one or more wound healing genes can be delivered to cells in the vicinity of a wound. Mechanical methods, such as microinjection, liposome-mediated transfection, electroporation, or calcium phosphate precipitation, can be used to introduce the coding sequence into cells in which it is desired to increase wound healing gene expression. Alternatively, if it is desired that the cells stably retain the construct, it can be supplied on a plasmid and maintained as a separate element or integrated into the genome of the cells, as is known in the art. The construct can include transcriptional regulatory elements, such as a promoter element, an enhancer or UAS element, and a transcriptional terminator signal, for controlling transcription of the coding sequence in the cells. Vectors, such as retroviral- or adenoviral-based vectors, can be used for this puφose. Recombinant retroviruses are described in numerous references, including Mann et al., Cell 33:153, 1983, Cane and Mulligan, Proc. Nat'l. Acad. Sci. USA 81:6349, 1984, Miller et al., Human Gene Therapy 1:5-14, 1990, and U.S. Patent Nos. 4,405,712, 4,861,719, and 4,980,289. Advenoviral vectors are preferred. The use of adenoviral vectors in vitro is described in Chatterjee et al., Science 258: 1485-1488 (1992), Walsh et al, Proc. Nat'l. Acad. Sci. 89: 7257-7261 (1992), Walsh et al., J. Clin. Invest. 94: 1440-1448 (1994), Flotte et al., J. Biol. Chem. 268: 3781-3790 (1993), Ponnazhagan et al., J. Exp. Med. 179: 733-738 (1994), Miller et al, Proc. Nat'l Acad. Sci. 91: 10183- 10187 (1994), Einerhand et al., Gene Ther. 2: 336-343 (1995), Luo et al., Exp. Hematol. 23: 1261-1267 (1995), and Zhou et al., Gene Therapy 3: 223-229 (1996). In vivo use of adenoviral vectors is described in Flotte et al., Proc. Natl' Acad. Sci. 90: 10613-10617 (1993), and Kaplitt et al., Nature Genet. 5:148-153 (1994). Other viral vectors, such as those based on togaviruses or alpha viruses, can also be used. A wound healing coding sequence can also be combined with a condensing agent, such as polylysine, polyarginine, polyornithine, protamine, spermine, spermidine, or putrescine, to form a gene delivery vehicle. Many suitable methods for making such linkages are known in the art. Alternatively, a wound healing coding sequence can be associated with a liposome to deliver the coding sequence to cells at the site of the wound. Other suitable methods of providing wound healing coding sequences include DNA-ligand combinations, such as those disclosed in Wu et al, J. Biol. Chem. 2(54:16985-16987 (1989). Wound healing coding sequences can also be delivered to the site of an internal wound, for example, using receptor- mediated targeted delivery. Receptor-mediated DNA delivery techniques are taught in, for example, Findeis et al. Trends in Biotechnol. 11, 202-05 (1993); Chiou et al., GENE THERAPEUTICS: METHODS AND APPLICATIONS OF DIRECT GENE TRANSFER (J.A. Wolff, ed.) (1994); Wu & Wu, J. Biol. Chem. 263, 621-24 (1988); Wu et al., J. Biol. Chem. 269, 542-46 (1994); Zenke et al., Proc. Natl. Acad. Sci. U.S.A. 87, 3655-59 (1990); Wu et al, J. Biol. Chem. 266, 338-42 (1991). Expression of a wound healing gene can be monitored by detecting production of mRNA which hybridizes to a delivered coding sequence or by detecting the protein product of the gene using, for example, immunological techniques. Expression of an endogenous wound healing gene in a cell can also be altered by introducing in frame with the endogenous gene a DNA construct comprising a targeting sequence, a regulatory sequence, an exon, and an unpaired splice donor site by homologous recombination, such that a homologously recombinant cell comprising a new transcription unit is formed. The new transcription unit can be used to turn the wound healing gene on or off as desired. This method of affecting endogenous gene expression is taught in U.S. Patent No. 5,641,670, which is incoφorated herein by reference. The targeting sequence is a segment of at least 10, 15, 20, or 50 contiguous nucleotides selected from the nucleotide sequence of a wound healing gene. The nucleotide sequences of the wound healing genes disclosed herein are available, for example, from Genbank, using the accession numbers provided in Table 14. The transcription unit is located upstream of a coding sequence of the endogenous wound healing gene. The exogenous regulatory sequence directs transcription of the coding sequence of the wound healing gene. Optionally, effective expression of one or more wound healing genes can be altered in cells which have been removed from a mammal, such as dermal fibroblasts or peripheral blood leukocytes. The cells can then be replaced into the same or another mammal with a wound, preferably to or within the vicinity of the wound to enhance healing of the wound. Alternatively, cells obtained from healer mice can be used to treat a wound in a mammal. Preferred cells include macrophages, stem cells, fetal liver cells, peripheral blood leukocytes, and bone marrow cells. Extracts from these cells can be prepared using standard methodologies and used for wound treatment. The cells or cellular extracts can be placed directly at the site of the wound to promote its healing. In another embodiment, protein products of wound healing genes whose expression is increased after wounding in healer mice can be applied directly to the area of the wound. Protein products of wound healing genes can be used in a pharmaceutically acceptable composition and can be applied topically, as is well known in the art and described below. The lowered capacity for wound healing which occurs in aged mammals, including humans, can be enhanced by suppressing T cell function, for example using an antibody which specifically binds to a T cell receptor (TCR) or, in experimental mammals, by genetically eliminating functional T cell receptors. Anti- TCR antibodies are available in the art or can be prepared using established methodologies. Optionally, a polynucleotide encoding a single chain anti-TCR antibody can be used. Anti-TCR antibodies can be administered to mammals, including humans, to reduce levels of functional TCRs. Sub-populations of TCRs can also be targeted. Wounds which can be treated using methods of the invention include, but are not limited to, cuts, stretches, tears, pulls, abrasions, burns, bone breaks, crushes, scrapes, contusions, bruises, and the like. Particularly, peripheral or central nerve injuries, such as crushed or severed nerves, including the spinal cord, can be treated. Methods and compositions of the invention can be used to treat and thus enhance healing of a wound by promoting processes such as angiogenesis, chondrogenesis, return of hair follicles and/or sebaceous glands, reepithelialization, rapid connective tissue proliferation, deposition of organized extracellular matrix, and restoration of normal tissue architecture and function. Surgical adhesions can be prevented by prophylactic treatment of surgical incisions using compositions and methods of the invention. These methods and compositions are useful in any situation in which regeneration or healing of a wound without formation of scar tissue is desired. Wound healing compositions of the invention can comprise a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers are well known to those in the art. Such carriers include, but are not limited to, large, slowly metabolized macromolecules, such as proteins, polysaccharides, polylactic acids, polyglycolic acids, polymeric amino acids, amino acid copolymers, and inactive virus particles. Pharmaceutically acceptable salts can also be used in wound healing compositions, for example, mineral salts such as hydrochlorides, hydrobromides, phosphates, or sulfates, as well as salts of organic acids such as acetates, proprionates, malonates, or benzoates. Wound healing compositions can also contain liquids, such as water, saline, glycerol, and ethanol, as well as substances such as wetting agents, emulsifying agents, or pH buffering agents. Liposomes, such as those described in U.S. 5,422,120, WO 95/13796, WO 91/14445, or EP 524,968 Bl, can also be used as a carrier for a wound healing composition. Administration of wound healing compositions of the invention can include local or systemic administration, including injection, oral administration, particle gun, or catheterized administration, and topical administration. For treatment of wounds on the surface of the body, a wound healing composition is typically prepared in a topical form, either as a liquid solution, suspension, gel, or cream. However, solid forms suitable for solution or suspension in liquid vehicles prior to injection can also be prepared, for local treatment of internal wounds. Both the dose of a particular wound healing composition and the means of administering the composition can be determined based on specific qualities of the wound healing composition, the condition, age, and weight of the patient, the type and extent of the wound being treated, and other relevant factors. The above disclosure generally describes the present invention. All references cited in this disclosure are expressly incoφorated herein by reference. A more complete understanding can be obtained by reference to the following specific examples which are provided herein for puφoses of illustration only, and are not intended to limit the scope of the invention. MATERIALS AND METHODS The following materials and methods were used in the examples described below. Mice. The MRL/MpJ-Eαs ,lpr (hereafter referred to as MRL/lpr) mice were obtained from the Jackson Laboratory (Bar Harbor, ME). C57BL/6 mice were acquired from the Taconic Laboratory (Germantown, NY). Mice were bred and maintained under standard conditions at The Wistar Institute (Philadelphia, PA). F,, F 2 and MRL/lpr backcross populations were generated to conduct the genetic studies. The female parent used for generating the F 2 and backcross animals was MRL/lpr. In the examples below, alleles derived from the C57BL/6 parent are designated B and the MRL/lpr-derived alleles are designated S. Phenotyping. A 2.1 millimeter through-and-through hole was made in the center of the cartilagenous part of both ears of six week old mice using a metal ear punch (Fisher Scientific, Pittsburgh, cat # 01-337B). The holes were measured at the time of wounding and followed for wound closure using a grid-etched reticle (Bausch and Lomb, 7x). Histology. Ears were removed with scissors by cutting at the base of the pinna. They were fixed overnight in 10% buffered formalin. To facilitate sectioning, they were held flat during fixation by inverting the lid of a processing cassette on the base and sandwiching the flattened ear by applying gentle pressure with a rubber band. Once fixed, ears were bisected across the widest point of the hole under a dissecting microscope, using a #10 scalpel blade. The two halves were then glued together with collodion, again using the dissecting microscope to obtain perfect alignment of the cut edges and hole margins. Because the collodion would most likely dissolve in reagents used to prepare specimens for paraffin embedding, the ears were sutured together using 5.0 silk on a 1 Vi inch straight Keith Abdominal cutting needle with a triangular point. Tissues were embedded in paraffin and sectioned so that the cut edges containing the hole margins were in the plane of the section. Sections were stained with hematoxylin and eosin or with Gomori trichrome stain. Genetic Analysis. Genomic DNA was prepared from the liver of each animal in the (MRL/lpr X C57BL/6) x (MRL/lpr X C57BL/6) F 2 population. Frozen tissue was homogenized and digested overnight with 100 mg/ml proteinase K. Samples were treated with two phenohchloroform extractions and one final chloroform extraction. Finally, genomic DNA was purified by an overnight dialysis against TE buffer. PCR primers, purchased from Research Genetics (Huntsville, AL), were employed to perform a genome wide scan of the mouse. Amplification was conducted using Boehringer Mannheim reagents with the following concentrations: IX PCR buffer, 0.375 mM dNTPs, 0.5 U/μls of Taq polymerase, 0.165 μM of each primer, and 160 ng/20 μls of genomic DNA. Cycling conditions include a 1 min at 95 °C denaturing, 35 to 50 cycles of 1 min at 94 °C, 1 min 30 sec at 55 °C, 2 min 10 sec at 72 °C, and a 6 min final extension at 72 °C. PCR products were resolved using 3% Metaphor agarose (FMC) and were visualized through ethidium bromide staining. This method was followed for the majority of polymoφhic markers. In the case of small base pair differences, PCR amplification was carried out using 32 P- ATP labeled forward primers as described (38). Radiolabelled PCR products were then fractionated by size on 6% denaturing polyacrylamide gels. Statistics. Genotype data was organized and analyzed through the use of Map Manager QT (39). For quantitative trait analysis, critical threshold values for significance of linkage were determined by the permutation test, based on a regression model developed by Churchill and Doerge (40, 41). The values for the additive model of inheritance were calculated in terms of a likelihood ratio statistic (LRS). The threshold in the F 2 under assumptions of the additive model for suggestive linkage is LRS≥ 3.3 and for significant linkage is LRS ≥ 10.7. The dominant, free and recessive models were also tested and did not show a significant difference (z ' .e., they were less than 18-fold different) in resultant p values. The additive regression model was used because it is the simplest model and because it is consistent with the mode of inheritance of the quantitative trait loci (QTL) determined in this study. It should also be noted that the use of the additive regression model does not assume the pattern of inheritance to be strictly additive and at present the degree of additivity and dominance has not been determined. The threshold values in the backcross are 3.7 and 11.8, respectively. Loci were named as healing quantitative QTL if they independently attained significance in either cross or a suggestive level of significance in one cross, confirmed in the other (p < 0.05). Microsatellite markers were evaluated individually for linkage to the healing phenotype, based on the threshold values. In addition, a mean healing score for markers closely linked to each healing QTL was calculated independently of other loci using ANOVA, using a Bonferroni Dunn post-hoc test for making the three possible pairwise comparisons in the F 2 , resulting in single-locus genotypic values (Table 3) (45). EXAMPLE 1 Kinetics and gross aspects of the wound healing phenotype. C57BL/6 and MRL mice were ear punched using a standard metal ear punch to create a well circumscribed circular surgical wound of about 2 mm in diameter at a site at which the thickness of the ear is considerably less than a millimeter. The animals used initially were within the 8-12 week young adult age range so that early developmental considerations would not be an issue. As can be seen in Figure 1, by day 15 maximal closure was achieved in the C57BL/6 with a 30% reduction in the original hole diameter, which remains stable. In contrast, the MRL achieves an 85% reduction in hole diameter by day 15 with complete closure by day 25. Re-examination of the ears on day 81 showed no further changes. In Figure 2, the closed MRL wound is evident and it is difficult to identify the original site of the hole since there is no fibrosis or scarring. EXAMPLE 2 Histological aspects of the wound healing phenotype. Histologic sections of healing ear punch holes were examined during the first two days after injury to determine if there was a defect in the ability of their epithelium to migrate across the cut edge of the dermis and cartilage, thereby allowing uninhibited connective tissue proliferation (Figure 3). However, not only did epithelium promptly migrate across the MRL wounds, but this change occurred one day earlier for MRL mice (day 2) than for C57BL/6 mice (day 3). Indeed, for MRL mice epithelium completely covered virtually all wounds examined after day 1. Epithelium covered all C57BL/6 wounds examined after and including day 3, except for one wound from day 5 (Figure 4A) which showed continued presence of eschar with migrating epithelium failing to bridge the cut edge. As ears were prepared for histology, two grossly observable differences were noted between C57BL/6 and MRL. First, for all time points, the tissue surrounding the wounds in the MRL ears was severely hyperemic when compared to that of the C57BL/6 wounds. Second, starting on day 4, and continuing on each succeeding day, a prominent annular swelling was observed around the MRL wounds that was absent for C57BL/6 wounds. Consistent with the grossly observable differences between the wounds, histological examination at each timepoint (5 days, Figure 4A; 10 days, Figure 4B; 20 days, Figure 4C) showed a marked difference in the degree of angiogenesis, cell proliferation, connective tissue matrix formation, fibroblast migration, and ECM deposition which occurred in the two strains. Also, the presence of hair follicles with accompanying sebaceous glands within the healing wounds was noted for both MRL and C57BL/6 wounds but appeared more prominent and numerous in MRL than in C57BL/6 wounds. At all of these time points, C57BL/6 wounds have shown limited progression beyond the cut cartilage margins and have a distinct paucity of epidermal hair follicles and sebaceous glands. In contrast, the MRL wounds show marked progress towards full closure due to extensive dermal proliferation and are well supplied with hair follicles and sebaceous glands in the new growth zone. ECM is laid down so as to preserve normal architecture, underlying connective tissue is hypeφlastic, and the epidermis is rich and thick. The ear cartilage layer has not significantly extended into the wound site beyond the initial cut margin. C57BL/6 and MRL ears are shown on day 81 after wounding in Figure 5. Numerous ingrowths of cartilage can be seen in the MRL ear that are absent from the C57BL/6 ear. The cartilage ingrowths are surrounded by numerous adipocytes which normally make uptthe minor subcutaneous or hypodeπnal layer connecting ear cartilage to dermis. It is not clear why fat cells have come to be such a prominent cell type by this time point. EXAMPLE 3 The pattern of inheritance of the wound healing trait is quantitative. Our initial findings on the hereditary nature of the wound healing trait can be seen in Figure 6 (upper panel). In these studies, mice were ear punched at 6 weeks of age and were examined at 2 weeks and 4 weeks after ear punching. The 4 week ear hole size of the MRL mice ranged from 0 to 0.4 mm, while the ear hole size of the C57BL/6 mice ranged from 1.2 to 1.6 mm. These two healing phenotypes were non-overlapping. Fifteen F, mice bred from MRL x C57BL/6 had ear holes intermediate between the two parents (ranging from 0.4 to 1.1 mm). In an initial experiment, two backcross populations were created by using (MRL female x C57BL/6 male) F, females and mating them to the parental males (Figure 6, lower panel). The backcross population to MRL displayed a curve skewed to MRL-type healing. In the backcross population to C57BL/6, the progeny showed a curve with its mean displaced to C57BL/6-type (i.e. poor) healing. The healing thus appears to be a quantitative trait. EXAMPLE 4 The pattern of inheritance of the wound healing trait. All MRL mice quickly and effectively close the wounds in their ears; C57BL/6 (B6) mice are unable to completely close their wounds (36). The F, has an intermediate phenotype, with considerable variability (Figure 7). Like the F„ the (MRL/lpr x B6)F 2 population demonstrates a bell-shaped curve of healing diameters (Figure 7). The backcross (BC1) population to MRL/lpr ((MRL/lpr x B6)F, x MRL/lpr ) displays a curve skewed to MRL/lpr -type healing, whereas in the backcross population to B6 [(MRL/lpr x B6)F, x B6], the progeny show a mean displaced to B6-type (i.e. poor) healing (36). The healing profiles of each of the populations used in this study are given in Table 1. The distribution of the variance in each of these populations compared to those of the parental and F, mice were used to give a rough estimate of the number of unlinked genes that contribute to this quantitative trait (42, 43). From this calculation, it is likely that at minimum three to four unlinked loci (QTLs) have an impact on the healing trait in this strain combination. EXAMPLE 5 Mapping ofSSLP markers and significant threshold values. A total of 436 S SLP markers were tested for potential polymoφhisms between the two strains of mice. Ninety two markers detected allelic variants in the parental strains and therefore were used for genotyping of the segregating populations. Markers were chosen based on their location in the genome, in an attempt to make a linkage map with an even spacing of 20 centimorgans between markers to generate a complete genome-wide scan (44). In regions where linkage to the healing trait was detected, the density of markers was increased to obtain a more accurate genetic dissection in the area of interest. Overall, genomic coverage reached -97.7 percent across the nineteen autosomes. Suφrisingly, despite the distant genetic relationship between these two inbred strains (13, 37), no polymoφhisms were found on the X chromosome (0/18 primers tested, data not shown). The 92 polymoφhic microsatellite markers were then used to map the wound healing regeneration trait in 101 mice from the (MRL/lpr X C57BL/6)F 2 intercross. For assessment of the probability of genetic linkage, critical values were calculated from this database using the permutation test (40; see Materials and Methods). The order of all markers in this linkage analysis was consistent with the order predicted by the available genomic maps (Whitehead Institute/MIT, and Mouse Genome Database, The Jackson Laboratory, Bar Harbor, ME: www.informatics.jax.org). EXAMPLE 6 Mapping of quantitative trait loci linked to the healing phenotype in the F 2 population. Table 2 shows all of the microsatellite markers that were positive for linkage to the healing phenotype in two crosses and Table 3 lists the healing scores for markers associated with wound closure. Table 9 shows microsatellite markers that were positive for linkage to the healing phenotype analyzed separately for male and female mice. In the F 2 cross, QTLs that contribute to the healing phenotype and are derived from MRL/lpr exist in three primary support intervals. Two of these QTLs are located on individual sites on chromosome 13, and are designated heal 2 and heal3. These QTLs are located as follows (with their corresponding microsatellite marker): heal2, on proximal chromosome 13, near D13MU115 ( p = 0.0019) and heal3, at a more distal location near D13MU129 (p = 0.0010). One of the two QTLs on chromosome 13 (heal3) has achieved significant likelihood of linkage to the healing trait while the other (heal2) is suggestive, though confirmed in a second cross (see below). Multiple markers near these loci show a suggestive level of significance, including for heal2 : D13MU135 and D13MU116 and for heal3 : D13MU53, D13MU151, D13MU144, and D13MU107 (Table 2). D13Ndsl and D13MU191 both achieved highly suggestive LRS values but the assignment of a QTL in this region is provisional at the present time because the 95% confidence intervals for these markers and the two flanking QTLs overlap (not shown). Nevertheless, there are distinct breaks between these QTLs in the level of significance for their linkage to healing with no deviation from the predicted order of these markers. A second region that contains a QTL with significant linkage to the healing phenotype was detected on chromosome 15, inthe region ofmarkerE>i5 / ' t24 (p = 0.0011). Other microsatellite markers mapping to this location which meet the criteria for suggestive linkage to wound healing include D15MU172 and D15M 14. We have designated this QTL heal4. In addition to the QTL on chromosome 13 and chromosome 15, which have MRL/lpr-derived healing alleles, a B6-derived healing QTL was mapped to chromosome eight, near the marker D8MU211, with a significant LRS value (10.7, p = 0.0011). Other markers in this location which showed linkage were D8M 132, D8MU166, and D8MU249. This locus was the first QTL identified and was designated heall. The contribution of each heal locus to the process of wound closure, as expressed by the single-locus genotypic values (45) (Table 3), generally fit an additive mode of inheritance, with the heterozygote healing score approximately halfway between the scores of the two homozygotes. One exception is the heal3 QTL, which may be recessive (i.e., heal3 ^ homozygotes show significantly better wound closure than either heterozygotes or heal3 b b homozygotes). In addition, the heal3 QTL appears to interact with heall to give the most completely healed ear holes (ANOVA, p=0.017). The average residual wound in heall ^ homozygotes is 0.73+0.27; however, in animals that are both heall b/b and heal3 sls , residual wound size is 0.53+0.30 (Figure 2). Conversely, in mice homozygous for heall ** but also homozygous for heal3 b b , the residual wound size is 1.2+0.22. Other pairs of heal QTLs also show these largely additive interactions, but do not attain statistical significance. EXAMPLE 7 Mapping of quantitative trait loci associated with the healing phenotype in the backcross. To confirm the linkage assignments seen in the F 2 , we conducted a small backcross study (42 mice), using (MRL/lpr x B6) F, females and MRL/lpr males as parents. The FI between MRL/lpr and B6 has an intermediate wound closure phenotype, and all progeny in this cross were expected to show intermediate to good healing. In fact, this was largely the case, although several mice in the backcross had poor wound healing. An analysis of this cross showed linkage to healing at locations that coincided with the supported intervals of association seen in the F 2 for both of the two QTLs on chromosome 13 (heal2 and heal3). These QTLs were near markers D13M US (LRS value = 5.0, p = 0.0261) and D13MU129 (LRS value = 8.3, p = 0.0040), respectively (Table 2). In addition, linkage to the healing phenotype was also detected on chromosome 12 (heal5) at marker D12M 132 with a LRS value of 10.9 (p = 0.0009) and at the closely-linked marker, D12MU233 (LRS = 9.4, p = 0.0022). This linkage was supported by suggestive linkage in the F 2 . The single locus genotypic value for residual wound diameter for the heal5 (D12MU132) QTL is also given in Table 3. Finally, a locus showing a highly suggestive LRS value of 10.2 (p = 0.0014) was found on chromosome 7 near marker D7M 220. EXAMPLE 8 Differential Gene Expression in Healer and Non-Healer Mice. Assays were carried out to analyze differential gene expression in healer versus non healer mice at different times during the healing process after ear punch. SAGE analysis. mRNA transcripts were identified and their levels quantitated using the SAGE technique, as described in U.S. Patent 5,695,937. In order to use SAGE for transcript identification and quantitation, messenger RNA (mRNA) was first prepared from the desired cell or tissue sample. Complementary DNA (cDNA) was then synthesized from the mRNA using standard techniques. The entire population of cDNA molecules was treated to create a single unique "tag" from each cDNA. These tags are listed in Tables 12 (C57BL/6) and 13 (MRL). The sequence of the tags serves to identify each transcript. The number of times each tag occurs measures the number of copies of the mRNA originally present in the biological sample. Tags can then be identified and quantitated. Gene expression data obtained from SAGE analysis of each tissue was stored in a database to facilitate multiple comparisons with gene expression in other tissues. Microarray analysis. Gene expression in wound tissue of healer and nonhealer mice and their progeny was analyzed using the Atlas Mouse cDNA Expression Array (Clontech). This array includes 588 genes that playT ey roles in a variety of biological processes. cDNA was synthesized from healing wound tissue from healer and nonhealer mice, labeled with 32 P, and hybridized separately to the arrays according to the protocol provided. After a high-stringency wash step and autoradiography, expression profiles were obtained. RT-PCR and Differential Display. The presence of known gene products in healing wound tissue was analyzed using RT-PCR and Differential Display analysis. cDNA was synthesized from RNA using reverse transcriptase. The cDNA was amplified using specific primers and displayed as fragments by gel electrophoresis for comparison. Quantitation was carried out using titrations of input material, and then samples were compared. This method is valuable for assessing the presence of known gene products and is relatively quantitative. Expression of candidate genes identified in the genome screen described above, were separated into the following groups. Group I comprises genes which may be directly involved in wound healing based on their mapping to a chromosomal locus identified in the genome screen. Group IA comprises genes in loci whose correlation with wound healing are statistically suggestive. Group IB comprises genes in loci whose correlation with wound healing are statistically significant. Group II comprises genes which are regulated by products of the mapped genes in Group I. The results of these assays are given in Tables 5-8. Differential expression of several candidate gene products were confirmed in two assays: MSX-2 or HOX8 (chromosome 13) and RARG (chromosome 15) were identified by both RT-PCR and microarray analyses at early time points. The gene encoding epidermal keratin (on chromosome 15) was identified by microarray at all time points and by SAGE analysis. Expression of RARG and epidermal keratin could be related, because retinoic acid (RA) causes growth of epidermal cells via the RA receptors in skin (i.e., RARG). Epidermal keratin would then be upregulated. EXAMPLE 9 Quantitative Trait Loci Associated with Healing. The Mouse Genome Database and associated literature were searched for potential candidates near the heal QTL (Table 4). The first locus, heall, located on chromosome 8, is derived from C57BL/6 and is one of the strongest QTL of the five (p = 0.0011), In the absence of contributing genes from MRL, C57BL/6 mice clearly cannot accomplish complete wound closure with heall alone. It has been shown that alleles that contribute to a trait from a parental strain that does not display that trait are not uncommon (46). Thus, it is not suφrising that heall shows a strong additive effect with MRL loci in the F 2 (see Figure 8). Candidate genes for heall (Table 4) in the strongest supported interval include the guanine nucleotide binding protein alpha 0, Gnao, an alpha subunit of a heterotrimeric G-protein which interacts with an activated G protein coupled receptor (Gp-cr), preceding downstream signaling (47). It is interesting to speculate that the basis of the additive interaction of heall with heal3 is an interaction between the gene products encoded by Gnao and the Gp-cr 18 found in the heal 3 interval. Though the method used for determining QTL cannot separate multiple loci in the same linkage group, we have observed highly suggestive LRS values for two regions of chromosome 13 in addition to the two QTLs identified (Table 2). That these may be unique QTLs is supported by the fact that they are separable from each other in phenotype congenics that have been generated (data not shown). One of these regions is located on chromosome 13, near marker D13ndsl. Msx2 (also known as Hox8) is found in this interval and is expressed in regenerating amphibian tissue (48) as well as regrowing fingertips in neonatal mice (49). In this regard, we have evidence that Msx2 expression is different in healing ear tissue between MRL and B6 mice (Samulewicz et al, manuscript in preparation). This difference could be due to a polymoφhism in the Msx2 gene itself, or to the indirect effect of an FGF signaling difference (50) mediated through the FGF receptor, FGFR4 (51), which is also encoded by a candidate gene located in this interval. Heal4 is found on chromosome 15 near marker D15MU244. The chromosome 15 QTL is strongly associated with the wound closure trait (p = 0.0011) and is located in an area rich in candidate genes, including the gene encoding retinoic acid receptor gamma (Rarg), members of the keratin family which influence differentiation in the epidermis, as well as developmental genes known as homeobox and wnt genes. The retinoic acid pathway is known for its role in regeneration in amphibians (32, 34, and 52). Furthermore, the gamma subtype of the RAR displays preferential expression over the alpha and beta subtypes in skin and cartilage tissues (53), which is the site where the MRL/lpr healing trait is evaluated in the present study. Finally, this set of genes does not include the fas gene, H-2, or any other gene known to play a role in the autoimmune profile of MRL/lpr mice. Several lines of evidence support this. First, our previous findings showed that the MRL/MpJ mice heal similarly to MRL/MpJ-Fαs lpr mice (36). Secondly, intervals containing wound-healing genes in our crosses showed no overlap with those from another report on the genetic analysis of MRL/lpr autoimmune phenotypes (17). Third, we tested the lymph node cell number, a parameter associated with lymphoproliferation, of each of 101 F 2 mice in a regression comparison with their healing phenotype, and no association was found with the healing trait (r 2 = 0.0002, p = 0.89) (Blankenhorn, et al., in preparation). The MRL/lpr mouse strain was originally selected for its large size (13, 37); it was subsequently found to have a major defect in immune regulation, due to a retrotransposon insertion into the second intron of the fas gene (16, 54). This mouse exhibits immunological defects closely mimicking those of the human disease, systemic lupus erythematosus (SLE) and other lymphoproliferative disorders (14, 15). In the present study, however, none of the five healing QTLs nor the highly suggestive regions identified displays linkage to the fas gene or other genes proposed thus far to control the other autoimmune phenotypes seen in this strain of mouse. EXAMPLE 10 Optic nerve regeneration in MRL mice. Healer (MRL/+) and non-healer (C57B1/6) mice were anesthetized and the optic nerve was cut using a micro-dissecting spring scissors from behind the left eye socket. The optic nerve was visually inspected to identify a cut end. The right eye was not touched. The mice were examined after 1.5 months. Tissue from both the control right eye and the left eye where the optic nerve had been transected was removed, fixed in formalin, and embedded in paraffin. Serial sections were made and stained with hematoxylin and eosin. Several tissue sections were destained and restained with Bodian's silver stain to visualize axons. In the all three non-healer mice the left eye had completely atrophied and had sunken into the eye socket while the control, right eye appeared normal (Figure 9B). There was no evidence of eye-specific tissue in the left socket, although lacrimal gland tissue was present. The optic nerve near the eye and the chiasm had disappeared. Thus, there was no evidence of the presence of any part of the left eye or the associated optic nerve remaining in these animals. In contrast, in all four healer mice the left eye had either only slightly sunken or was of normal size when compared to the right (control, non-treated) eye which was normal (Figure 9A). The optic nerve could be found in both eyes of all four healer mice and the chiasm appeared normal. The right (control, non-treated) optic nerve appeared normal in each case. Histologic sections of eye-specific tissue from both healer and non-healer mice were examined 1.5 months after the optic nerve of each mouse's left eye had been surgically transected. In the healer mice, longitudinal serial sections of the right (control) eye tissue exhibited a normal, uncut optic nerve (Figure 10). However, histologic sections of tissue from the left eye of healer mice demonstrated, in the first and last sections, a cut optic nerve (Figure 11). More importantly, the middle histologic sections exhibited an increasing neural connection between the cut regions of the optic nerve. Figure 11 shows an example of a restored optic nerve region as being thinner and irregular when compared with the uncut optic nerve of the (control, non-treated) right eye shown in Figure 10. Further, there appeared to be connective tissue and infiltrating macrophages filled with melanin as well as a proliferation of glial cells, especially oligodendrocytes, in the left eye-specific tissue of healer mice. Additionally, a blood vessel can be seen running along side the restored optic nerve in Figure 11. This observation is important because cross-sections of uncut normal and healer optic nerves have blood vessels which run along side and are embedded into the optic nerve. These blood vessels would have been unavoidably cut upon transection of the optic nerve. Thus, it appears that the healer mice demonstrated regrowth of the blood vessels running along the restored optic nerve in addition to regeneration of the optic nerve itself. Several sections were then destained and restained to visualize axons with Bodian's silver stain. As can be seen in Figure 12A, the healer uncut (right) eye has bundles of nerves woven through the optic nerve. On the other hand, the cut (left) healer optic nerve (shown in Figure 12B) has a left optic nerve which appears to be generally depleted of nerve fibers. On the side of the healed optic nerve nearest to the eye, nerve fibers can be seen growing towards the brain. These fibers can be seen leaving a nerve cell body and having directionality (Figure 12B). Near the newly grown nerve fibers are an abundance of oligodendrocytes. Thus, healer MRL mice can regenerate nerve tissue. More specifically, all four MRL mice in which the left optic nerve was transected exhibited regrowth of the optic nerve within 1.5 months after transection. In these mice, the left optic nerve has clearly been cut but a neural connection was reestablished, with marked cellular proliferation including infiltrating macrophages filled with melanin and oligodendrocytes. Further, vascular connections had also been reestablished in the left healer eye as demonstrated by the presence of a blood vessel running along the side of the restored optic nerve. By comparison, the non-healer mice had no eye- specific tissue in the left eye socket and no nerve regeneration was detected. Nerves which have been examined using the above-described procedures are the peripheral nerve, including the sciatic nerve, and central nervous system nerves including the optic nerve, brain stem and spinal cord. EXAMPLE 11 Restoration of function in MRL mice following sciatic nerve crush. Three strains of mice, C57BL/6, MRL and A J, were examined after sciatic nerve crush. The percent of sensory function index (SFI), which is related to sciatic nerve function, is the comparison of the gait of the mouse having a normal left and a cut right sciatic nerve. To measure the SFI, the footpads of the animals were inked, and the animals were allowed to walk on a paper pad in a housing which forces them to walk forward. The pattern of ink deposition is directly related to the SFI, which was then calculated for each mouse. The results of these experiments are shown in Figure 13. Significant recovery of sciatic nerve function was observed in MRL mice (50% of 2/3 mice) at day 30. In contrast, C57BL/6 and A/J mice exhibited an average negative SFI value, indicating that the sciatic nerves in these animals did not recover. EXAMPLE 12 Involvement ofT cells in healing in aged healer mice. Several facts indicated that T cells might play a role in wound healing in aged healer mice. First, scarless healing occurs in fetal mice until embryonic day 16, when T cells develop in the thymus. Second, in MRL/lpr mice, the number of lymphocytes increases with age. Third, aged healer mice do not heal as well as younger healer mice (Figure 17). We therefore examined the role of T cells in the enhanced healing response of these mice in two ways. First, we treated aged (5 month-old) healer mice with antibodies against T cell receptors and punched a 2 mm ear hole in the treated aged mice. As measured by this assay, aged mice which were treated with anti-TCR antibodies became complete healers, similar to their younger counteφarts (Figure 18). Second, we crossed a member of the F, generation from a cross between a healer and a non-healer mouse whose T cell receptors had been genetically eliminated, or "knocked out." Members of the resulting F 2 generation were then examined for a healer phenotype using an ear punch assay and for the presence of T cells by flow cytometry. Approximately 12% of the F 2 generation had no T cells and were complete healers. (Figure 19). These results suggest that T cells somehow suppress the healing response in aged healer mice and that elimination of functional T cells restored the healing capacity of the mice. T cells obtained from non-healer mice can now be transferred into healer mice to determine whether the T cells, or a particular population of the T cells, have an effect on the enhanced wound healing of healer mice. EXAMPLE 13 Adoptive transfer of fetal liver cells from healer mice into X-irradiated non-healer recipients enhances wound healing. C57BL/6 mice were lethally irradiated. After 24 hours, each mouse received an injection of fetal MRL liver cells into the tail vein. Ear punches were performed at 2, 4, and 6 months after injection of the liver cells. No healing was observed in the ears of mice after 2 or 4 months. After 6 months, however, ear holes of the C57BL/6 (non-healer) mice exhibited a healing response. This response was correlated with the detection of chimeric cells in the thymus and/or lymph node of the mice, as shown in Figure 20. Thus, it is possible to transfer the ability to heal ear holes to adult non-healer mice using adoptive transfer of fetal liver cells from a healer mouse strain. EXAMPLE 14 Adoptive transfer of macrophages obtained from healer mice to non-healer mice recipients enhances wound healing. The MRL mouse is derived from crossbreeding of LG (75%), AKR (12%), C3H ( 12%) and C57BL (0.3%) mice. Wild type strains of these mice were tested for their ability to heal or to partially heal 2 mm ear hole wounds. The only mouse which exhibited partial healing was the LG mouse (Figure 14). The experiment was conducted as described herein for the MRL mouse. Normal C57BL/6 mice were injected intraperitoneally with macrophages obtained from healer mice at the time of ear punching of the non-healer mice. The macrophages which were transferred were five day thioglycollate induced peritoneal cells obtained from an (MRLxB6)F 2 T cell receptor alpha chain knockout mouse. This mouse was used because the β+ T cells were absent and the cells were only partially allogeneic. Macrophages were obtained from healer mice using standard procedures, selected by adherence to plastic, and transferred to non-healer mice. Uninjected non-healer mice and non-healer mice injected with non-healer macrophages served as controls in the experiment. Ear hole closure was measured during the 30 days after wounding. The results of the experiment are shown in Figure 15. Healer macrophages induced the best ear closure (greater than 75%) in nonhealer mice. (Figure 21). Macrophages which were obtained from non-healer mice and which were transferred into non-healer mice were unable to confer healing on non-healer mice. These results establish that tissues and cells obtained from healer mice can be used to confer healing ability on non-healer mice. EXAMPLE 15 Functional recovery of healer mice following complete transection of the spinal cord. A complete transection of the spinal cord at thoracic level (TH9-TH11) was made in MRL and in C57BL/6 mice anesthetized with ketamine/xylazine (100/15 mg/kg, i.p.). A dorsal median incision was made over the lower thoracic vertebra. Retractors were placed in the wound to allow surgical manipulation. After exposing the vertebral arch and the spinous processes by retracting the medial part of the autochtone musculature, the osseous parts of one vertebral bone were removed with a milling cutter, leaving the dura mater intact. After continuous cooling of the spinal cord with ice cold isotonic saline to minimize bleeding, transection was performed with a scalpel. In some mice, a portion of the spinal cord was removed, rather than simply cut. In these mice, more of the spinal cord is exposed, by removing only the caudal part of the more cranial vertebral arch. The cranial part of the more caudal vertebral arch was also be removed to minimize vertebral instability. Two transections were performed, and the tissue between the transections was removed with a fine forceps. Ice cold isotonic saline was then applied in pulses until no bleeding occurred. The muscles of both sides were repositioned and gently opposed by single 8-0 resorbable sutures. The skin was closed in the usual manner with single sutures using 8-0 Dexon (Polyglycolic Acid). Animals were weighed daily to ensure proper water and nutritional intake. Food and water was made available at ground level through a special device. In the first postoperative days, each mouse was watched carefully for its ability to eat and drink, unless it was fed manually. The bladder was emptied 3 times a day by applying gentle pressure to the abdomen. The mice were also carefully watched for potential injury and self mutilation due to loss of innervation of the hind limbs. After 2 days of postoperative recovery, the mice were examined for loss of lower limb innervation. Both strains showed no innervation of the hind limbs, which were dragged behind. After 2 weeks, neither strain of mice showed signs of innervation of the hind limbs. Between seven and nine weeks, however, MRL mice regained partial proximal innervation of the tail and lower limbs, exhibiting the ability to flex and then extend their hind legs. C57BL/6 mice continued to show no movement of the hind limbs or tail and to show degeneration of the limb musculature and fixed flexion of the joints. In contrast, fixed flexion of the joints of the MRL mice never occurred, and only minor muscle degeneration was in the observed first month. Histological examination revealed that MRL mice produced only a minor scar between the two ends of the transected spinal cord (2-5 cell layers), whereas C57BL/6 mice produced a conventional glial scar (10-15 cell layers), thereby preventing the spinal cord to reconnect on an axonal level. The partial functional recovery in MRL mice, as well as the underlying histomoφhology, suggests that regeneration and reconnection on the axonal level of the spinal cord of MRL mice can occur after complete transection of the spinal cord. EXAMPLE 16 Differential expression of genes in dendritic cells of healer and non-healer mice. Dendritic cells (immature macrophages) were isolated from the bone marrow of adult C57BL/6 and MRL + mice using standard procedures. Total RNA was isolated from the dendritic cells and subjected to microarray analysis, as described above in the Materials and Methods section. Table 15 shows genes which were increased more than 50% in either MRL + or C57BL/6 mice. The gene names and array locations are from the Clontech web site (http://www.clontech.com clontech JAN98UPD/Atlaslist.html). EXAMPLE 17 An in vitro assay of wound healing. A hole was punched in the ear of a healer and a non-healer mouse. Two days later, an explant of the ear tissue, including the punched hole, was excised, embedded in a collagen gel, and maintained in vitro. Figure 22 shows explants of healer (Figures 22 A, B) and non-healer (Figures 22C, D) ear punch explants in vitro. Figure 23 shows cells migrating away from the explant of the healer ear punch, possibly in response to factors which are produced by the wounded ear. EXAMPLE 18 Adoptive transfer of bone marrow-derived dendritic cells from healer mice into nonhealer immunodeficient mice enhances healing. Dendritic cells were isolated from healer (MRL + ) and non-healer (C57BL/6) mice as described in Example 16. C57BL/6 Rag " ' " mice, which are immunodeficient and unable to reject the dendritic cells, were ear-punched to make a 2 mm hole and immediately injected intraperitoneally with dendritic cells of either MRL + or C57BL/6 mice. Ear hole closure was measured at 0, 2, 5, 10, 18, 24, and 27 days after wounding. The results of this experiment are shown in Figure 23. Healer dendritic cells induced the best ear closure (approximately 90%) in the non-healer mice, demonstrating that the healer dendritic cells can be used to transfer enhanced healing ability to non-healer mice. EXAMPLE 19 Segregation of quantitative trait loci in phenotype congenic mice. Congenic mice were generated by six successive back-crossings of the F, generation of a healer (MRL) x non-healer (C57BL/6) cross with its non-healer parent strain. Segregation of quantitative trait loci was examined in healer phenotype congenic mice (see Examples 5-8, above). Each of the 17 phenotype congenic mice examined healed a 2 mm ear hole from at least 75% to 100% 30 days after punching. Table 16 shows that only certain markers segregate with the healer phenotype in these phenotype congenic mice. These mice are therefore useful for dissecting out the minimum number of chromosomal loci and genes involved in enhanced wound healing. Table 1. Residual wound size Parental strains and hybrid Backcross and intercross progeny C57BL/6 1.10+0.27 FI x MRL/lpr 0.35 + 0.27 MRL/lpr 0.04+0.06 FI x B6 0.95 + 0.25 (MRL x B6)F1 0.73+0.22 (MRL x B6)F2 0.83 + 0.28 Numbers are the diameter of holes in mm + standard deviation (SD) on day 28-30. FI = (MRL~x C57BL 6)F1 hybrid. Table 2. Location of heal QTL as determined in the intercross (F2) and the backcross (BCl) progeny. MGD F2 F2 BCl BCl QTL cM Primers LRS' p value LRS 2 — p value 71.5 DlMit288 6.1 0.0130 ns 105 D2Mitl48 nd 4.8 0.0279 55.6 D4Nds2 4.2 .4.2 0.0400 ns 77.5 D4Mitl27 5.5 0.0190 ns 52.4 D7Mit220 ns 10.2* 0.0014 21 D8Mitl91 ns 6.4 0.0115 33 D8MU132 5.5 0.0188 ns 37 D8Mit249 7.3 0.0069 ns 49 D8Mit211 10.7 0.0011 ns heall* 56 D8Mitl66 7.3 0:0068 rd 34 D12Mit4 ns 7.1 0.0077 52 D12MU233 fi . 0.0137 9__4_ 0.0022 52 D12M 132 nd 10.9 0.0009 heal5*' 9 Dl3Mitl35 9.4 0.0022 4.8 0.0290 11 D13MRT15 2 0.0019 5 1 0.0261 heal2*' 13 D13M T16 8.7 0.0030 5.1 0.0230 30 D13Mit245 7.5 0.0335 nd 32 D13Ndsl 10.2* 0.0014 ns 44 D13Mitl26 7.4 0.0065 ns 44 D13Mitl91 10.2* 0.0014 ns 47 D13Mit29 6.5 0.0101 nd 48 D13Mitl07 7.4 0.0064 ns 49 D13M 144 6.9 0.0088 nd . 60 D13Mitl29 10.8 0.0010 2 0.0040 heal3** 62 D13Mit53 10.5 0.0012 7.1 0.0077 71 D13MU151 8.2 0.0042 4.6 0.0318 54.5 D15MU171 6.6 0.0104 nd 55.6 D15Mit242 7.1 0.0079 nd 57.8 D15MR172 7.3 0.0070 nd 56.8 D15MU244 10.7 0.0011 nd hea!4* 56.8 D15MU14 8.5 0.0035 ns Underlining indicates the LRS values that were used for assigning heal QTL. Footnotes: 1, Threshold LRS for significant linkage = 10.7, and for suggestive linkage. 3.3 2, Threshold LRS for significant linkage = 11.8, and for suggestive linkage, 3.7 *, see text for discussion #, confirmed in second cross Table 3. Single locus genotypic values for heall to healS. D8M 211 (heall) D13Mitll5 (heal2) Genorvpp; avg tdev p avp stftev β b/b 0.73 0.27 0.0319 0.96 0.25 0.0904 b/s 0.84 0.27 0.1214 0.84 0.29 0.0567 s/s 0.95 0.28 (yX)13*** 0.72 0.26 0.0024*** D13MitI29 (heal3) D15Mit244 (heal4) avp stdev β avg stdev β b/b 0.96 0.28 0.2156 0.95 0.19 0.0485 b/s 0.84 0.22 0.0141** 0.86 0.30 0.0677 s/s 0.74 0.34 0.0022*** 0.70 0.27 0.0013*** D12M 132 (healS) avg stdev β b/s 0.51 0.40 0.0005*** s/s 0.15 0.32 Averages and standard deviations for wound diameters at day 30 are given for mice sorted by the genotype of markers near each healing QTL. *, p values in the F2 are listed vertically for b b vs. b/s, s/s vs. b/s, or bib vs. s/s; in the backcross, p values are for the heterozygote b/s vs. the homozygote s/s. Genotype values are significant at α=0.05 (**) or α=0.01 (***) in post-hoc analyses. Table 4 Candidate genes in genomic intervals containing QTLs QTL MGD cM Candidate genes in interval lieall 33 Comp, cartilage oligomeric matrix protein 39 pdw, proportional dwarf 42 Os, oligosyndactylism 46 GnaO 51.5 to 67 Cadherin family heall 7 Nid, nidogen 8 Gli3. GLI-Kruppel family member GLI3 10 Amph, amphiphysin 10 Inhba, inhibin beta-A 10 Rasll, Ras-like, family 1 heal3 32 Msx2, hox8 32.5 Fgfr4, fibroblast growth factor receptor 33 es, mesenchymal dysplasia 36 Tgfbi, transforming growth factor induced 44 Cspg2, chondroitin sulfate proteoglycan 45 Rasa, ras p21 GTPase activating protein 56 Gpcrlδ, G-protein coupled receptor 18 62 Itga 1,2, integral alpha 2 (Cd49b) heal4 51.6 Pdgfec, platelet derived growth factor 56.8 Col2al, procollagen, type II, alpha 1 56.8 Elal. elastase 1 57 Emb, embigin 57.1 Hoxc, homeo box C cluster 57.1 Rarg, retinoic acid receptor, gamma 57.5 Dhh, desert hedgehog homolog 58.7 Krt2, keratin gene complex 2 60 Itga5, integrin alpha 5 61.1 Itgb7, integrin beta 7 63 Glycaml adhesion molecule liealS 40 Fos, FBJ osteosarcoma oncogene 41 Tgfb3, transforming growth factor, beta 44.6 ChxlO, C elegans ceh-10 homeo domain con 45 Pgf. placental growth factor Table 5. Differentially expressed or regulated genes identified using microarray analysis of mRNA obtained from healing tissue on days 5 and 20 after ear punch compared to tissue obtained on day 0. Gene Group* Chromosome # Gene IA 1 Stat 1 1 PAI-2 2 ABI-2 2 Integrin alpha 2 Basic domain transcription factor 2 SEF-2 4 TNFR-1 4 SKI 7 H-ras 7 Cathepsin D 8 Glutathione Reductase 10 TIMP-3 10 STAT6 11 ACE 11 Macrophage inflammatory Protei: 11 c-erb 14 BMP-1 14 Cathepsin B 16 HMG 16 ETS 18 c-FMS IB 2 CRAPBII (RA binding protein) 2 CD44 2 SKY proto-oncogene 8 Casein kinase 12 YY1 12 c-AKT 13 GTT 13 SPI-3 13 GKLF 13 Cathepsin L 13 PDGF signalling molecule 13 thrombin receptor 15 epidermal keratin * Genes in Group II are listed in Tables 10 and 11. Table 10 is a list of genes which are differentially expressed on days 5 and 20 after ear punch between control mice (B6 & F 2 nonhealers) and experimental mice (MRL & F 2 healers). Table 11 is a list of genes which are regulated in MRL tissue from 0, 24, and 40 hrs after wounding or ear punching (see Figure 16). Table 6. Differentially expressed or regulated genes identified using RT-PCR analysis of mRNA from healing tissue. Gene Group Chromosome # Gene IB 13 MSX-2 15 RAR-gamma Table 7. Differentially expressed genes in Groups I and II identified using differential display analysis of mRNA from healing tissue.* Gene Group Chromosome # Gene IB 8 ecadherin II PMG-1 TR 2-11 tropomyosin * RNA from healer and nonhealer ears on days 0, 5 and 20 after ear punching were analyzed by RT-PCR. Random primers obtained from "Gene Hunter Corp" were used to amplify bands. Since these are random primers, the products are unknown but can be sequenced. It is a useful way of examining what amplifies in one population and not another. Thus, one has to compare what is present or not in B6 and MRL for each time point and then subtract out the differences seen in day 0. Table 8. Differentially expressed genes from Groups I and II identified using SAGE analysis of mRNA from healing tissue. Gene Group Chromosome # Gene IB 15 epidermal keratin II macrophage ferritin heavy subunit est (1758377)and see Table D Table 9 Microsatellite Markers Linked to Male and Female Healer Mice Table 9, cont. Table 10 Wound Healing Gene Products Identified by Microarray Analysis OS ^^ ON 0\ υ C, 0 O Table 10, cont. VO © "E_ "E_ 13(8) Ghitathtone peroxldase (plasma protein); aelenoproteln ae_ 8(16) G itathfane reductase DOWN DOWN Gfutathtona S-transferase (mlcrosomal) down(male) Grutathtonβ S-transferase Mu 1 υ up down 12(58) c-Akt proto-oncogene: Rac-alpha: protelne klnase B (PKB) 0. MB_ down FUP-L: apoptosb Inhibitor: FLICE-flke Inhibitory protein up(lemlae) down(lemale) 3(70.5) Gadd4S; growth arrest and DNA-damage-lnducible protein up_ Nm23-M2; nudeoskte dlphosphate Wnase B; metastasis-reducing protein; c-myc-related transcription factor up(male) down(male) Protein tyroslne phosphatase up(male) down(lemale) 19(23) RIP cell death protein: Fas APQ-1 (CD95) Interactor, contains death domain UP DOWN 13(16) SPI3; serprπ; similar to human proternase Inhibitor 6 (placental thro bln mhlbrlor) serlne protelnase Inhibitor IP DOWN 4(75.5) Tumor necrosis factor receptor 1; TNFR-1 - J up(lemale) UP(lemale) PA6 stromal protein; RAG1 gene activator HE_ MHR23B; Rad23 UV exdsten repair protein homologue; xeroderma pigmentosum group C (XPO repair complementing protein ' H£_ 2(45) AbrphBln-1 (abl-1) similar to HQXD3 I x-14 Adlpocyte dHlerentlatloπ-assoclated protein H»NH H»NH 2(91) Baste domaln leudne zipper transcription factor ϋ-L Butyrale response factor 1 NH»H NH»H CACCC Box- binding protein BKLF up DP-1 (DRTF-pollpeptlde 1) cell cycle regulatory transcription lactor down(lemale) up(lemale) 16(68.5) Ets-2 transcription factor down (lemale) up(lemale) 2(7) GATA-3 transcription factor down(lemale) up(lemale) 13(16) Qut-speclHc ruppeHlke factor GKLF down(lemale) up(lemale) 16(69) HMQ-14 non htstone chromosomal protein HE. NH>H Interferon regulatory factor 2 (IRF 2) up NH>H NF-1B protein (transcription factor) up_ down 15(61.7) Nuclear factor related to P46 NF-E2 up(male) down(male) 9(36) Nucfear hormone receptor ROR-ALPHA-1 up_ down β(syntenlc) Split handloot gene down(lemale) up(lemale) 12(64) Retlnoto add binding protein II cellular (CRABP-II) down (lemale) up(lemale) Rellnold X receptor Irrtfefaaing protein (RIP 15) HE_ down Transcription lador 1 for heat shock gene up_ Transcription lador CTCF (11 zinc fingers) NH»H up(lemale) 2(94) Transcription lador SEF2 down(lemale) up(lemale) YB1 DNA binding protein 1*1 up(lemale) up(female) 12(53) YY1 (UCRBP) transcriptional fador NH»H downtl) up(female) Ad n type I receptor up(male) down (male) C-C chemokine receptor (Monocyle chemoattradant protein 1 receptor (MCP-1RA) <7\ down(lemale) down (female)! Growth fador receptor NHx»H up up 8(20) Gluoocortlcbid receptor form A ϋE_ 6(31.5) CD31 (Platelet, endothellal cell adhesion molecule 1) up_ 2(56) CD44 antigen 9(66) Dystrogrycan 1 I "P down Glulamate receptor channel subunrl gamma Table 10, cont. m o Table 11. Genes whose expression is altered in MRL mice 0 hrs., 24 hrs., and 40 hrs. after ear punch. Block A Block B Block C Block D la. APC 1a. HSP-27 1a. Caspase -11 1a. abi-1 1b. BRCA1 1b. HSP-60 1e. bag-1 1j. BKLF 1e. EB1 lc. HSP-84 1f. Bak 1k. C/EBP 1f. ezrin 1d. HSP-86 1g. Bax 2g. DP-1 1L NF2 1f. Osp-94 2a. GTT tmfs. 2j. Elf-1 1j. p107 1j. cyplbl 2b. GTT Mu-1 3m. HMG-14 1l. p53 2e. Glutl 2d. GST pi-1 3n. Hox1.1 2a. maspin 3d. CXCR4 2e. A20 znc fnger pr. 4g. Hox 8 2d. VHL 3f. Prostaglandin E R 2k. c-Akt 4m. LKLF 2g. c-erb 3g. Tie-1 3a. CHOP 10 4n. Lbx1 2j. TTF-1 3j. Vegfr-2 3b. Clusterin 5a. Mph-1 21. c-myc 4h. TANK 3f. Fas1 R 5b. MRE 3b. FLI-1 4k. Tristetraproline 4c.Nm23-M2 5h. NF-E2 3e. Gli 5b. Hck 4g. PtPhosphatase 5m. DSS-1 31. B-Raf 5f. CamK 4h. PS-2 5n. Sox3 4e. PDGFRa 5h. Erk1 5a. TDAG51 (fas reltd) 6b. PAX-6 4g. SKl 5j. Jak3 5b.TNF 55 6f. RXR-6 4j. Vegfr-1 6h. PKC-theta 5d. TNFR-1 6g. RIP-15 4n. c-Src 6k. PI3-K 6j. MHR23B 6i. TF-1 for HSP 5c. H-ras 7b. Rab-2 7b. PCNA 7e. SEF2 5d. LFC 5j. b-protachykinin 7j. Gaplll 7c. bluelight R 7g. SP2 5m. IGFBP-2 6a. cyclin A 7n. Zyxin 7e. Pur 6d. cyclin B2 6h.cyclin D3 7k. HR6B 7b.p58/GTA 7e. cdk inhibit prot. 7n. XRCC1 7j. cdc25a 7m. prothymosin a Table ll. cont. Block E Block F lc. BMP-R 6m. dystroglycan 1b. BMP-1 5i. epid.k-18 1g. CSA-R 6n. glutamate R 1d. BMP-4 5k. epiderm keratin 2b. FGFR-4 7a. CD49b 1g. Cek 5 5n. kinesin 2e. GMCSF-R 7c. CD51 1h. Cek 7 6b. nonmuscle myos. 21. INFab-R 7g. integrin beta 1J.EGF 6d.vimentjn 2m. INFg-R 7i. ICAM-1 2a. G-CSF 6e.unconv myosin VI 3a. lL-1R 7j. Laminin R 1 2i. IGFBP-6 6g. cathep B 3c. IL2-R 71. Neuronal prot F3 2k. IGFBP-3 6h. cathep D 3d. IL3R 7n. VLA-3 21. IGFBP-4 6i. cathep H 3g. IL-7R 2m.lGFBP-5 6j. cathep L 3h. IL8-R 3a. ILGF-14 6k. collagenase IV 31. Estrog R 3c. K-FGF 6m. CTLA-1 3j. Androg R 3g. MIP2 6n. gelatinase B 3m. Glucocort R 3h. MADR2 7b. MMCP-4 4a. insulin R 3j. Smad 1 7c. MTMMP 4b. IRS-1 3k. NGF 7e.TPA 4h. Serotonin R 1e-b 3m. neuroleukin 7g. Protease Inhib 2 4j. Serotonin R 3 3n. oncostatin 7i. PAI-2 4m. Adrenergic R beta 1 4d. thrombomod. 7j.Spi-2 5c. GPCR 4g. TGFb2 7n. TIMP-3 5f. GABA-A 3 5b. IL-4 5g. GABA-A 4 5c. IL-6 51. P-selectjn 5d. IL-7 5m. catenin alpha 5e. cardiac myosin 6a. CD2 5g. CDC42 bind. prot. 6h. CD1 5h. epidermal keratin -14 Table 12 SAGE Analysis of C57B /6 Mice Five Days After Wounding SearchName = B5BANK FileName = c:\sage\data\b5data~1\b5bank.bag Anchoring Enzyme = Nlalll - CATG Tag Length = 11 DiTag Length = 24 Total Files = 56 Total Tags = 1508 Total Duplicate Dinners = 0 Tag Abundance Report Total tags after excluding tags = 1508 Count Percent Tag Sequence -Tag BaseFour Number 16 1.061 GGCTTCGGTCT - 2750136 13 .862 AGAGCGAAGTG - 563247 12 .7957 AGCAGTCCCCT - 601432 12 .7957 GTGGCTCACAA - 3054865 10 .6631 AGGCAGACAGT - 673868 9 .5968 GCTGGCCCTTC - 2598270 8 .5305 AGGTCGGGTGG - 711355 8 .5305 CGCCGCCGGCT - 1664424 7 .4641 CTGCTCAGGCT - 1995944 7 .4641 TGGGCATCCAC - 3838802 6 .3978 AAGGAAATGGG - 164075 6 .3978 ATACTGACATT - 817232 6 .3978 CCTTTGTGACT - 1571720 6 .3978 GAACATTGCAC - 2117522 6 .3978 GGGAAGGCGGC - 2755178 5 .3315 ATGACTGATAG - 925235 5 .3315 CACAAACGGTA - 1114541 5 .3315 CACCACCGTTG - 1131967 5 .3315 CAGAACCCACG - 1180999 5 .3315 CCCTGAGTCCA - 1434325 5 .3315 CCCTGGGTTCT - 1436408 5 .3315 GCCCGGGAATA - 2451981 5 .3315 GCGGCGGATGG - 2529851 5 .3315 GGAAGCCACTT - 2630944 5 .3315 TAAAGAGGCCG - 3154583 5 .3315 TATGTCAAGCT - 3388456 5 .3315 TGGGTTGTCTA - 3849949 5 .3315 TGTAGTGTAAT - 3878596 5 .3315 TTCAGTGGACC - 4009606 5 .3315 TTGGTGAAGGA - 4110377 4 .2652 AGAAACCAATA - 525581 4 .2652 AGTGAGGAAGA - 756233 4 .2652 ATAATACATAA - 799025 Table 12 , cont. 4 .2652 ATACTGAAGCC - 817190 4 .2652 ATTCTCCAGTG - 1013039 4 .2652 CAAACTCTCAC - 1056210 4 .2652 CAGTCACCAAC - 1233218 4 .2652 CCCACAAGGTA - 1380525 4 .2652 CCTTGCTCAAT - 1566532 4 .2652 CC 1 1 1 GAGATC - 1570958 4 .2652 CTAGTCTTTGT - 1882108 4 .2652 CTGAACATCTC - 1967326 4 .2652 GGCAAGCCCCA - 2689365 4 .2652 GGCCTGGCTTA - 2718333 4 .2652 TCCCCGTACAT - 3496724 4 .2652 TCCCTATTAAG - 3503043 4 .2652 TCTTCTCACAA - 3661073 4 .2652 TGGCCCAAATT - 3822608 3 .1989 AAGGTGGAAGA - 178697 3 .1989 ACATCATAGAT - 316196 3 .1989 AGGAAGGCGGC - 658026 3 .198& ' CAAGTGGAAAA - 1096193 3 .1989 " CACGCTCCCGG - 1154395 3 .1989 CAGGCCACACA - 1217605 3 .1989 CCAGAACAGAC - 1343778 3 .1989 CCCAGAGCACT - 1385032 3 .1989 CCCTAAACTGA - 1425529 3 .1989 CCTGATCTTTA - 1543677 3 .1989 CCTTTAATCCC - 1568982 3 .1989 CTCAACAGCAA - 1901713 3 .1989 CTCCTGGACAC - 1931794 3 .1989 CTGGCTTTCAG - 2006995 3 .1989 GACTTTGGAAA - 2227841 3 .1989 GAGCG I M I GG - 2256891 3 .1989 GATGACACCAG - 2327635 3 .1989 GCTGCAGTTGA - 2593529 3 .1989 GCTGCCCTCCA - 2594261 3 .1989 GTCTGCTGATG - 3008399 3 .1989 GTGGAGGCGCC - 3050086 3 .1989 GTGGGCGTGTA - 3057389 3 .1989 TAAACCTGCTA - 3151773 3 .1989 TATCCCACGCC - 3363942 3 .1989 TCGGTTTCTGC - 3587962 3 .1989 TCTCACCACCC - 3622166 3 .1989 TGACCCCGGGA - 3691945 3 .1989 TGCACAGTGCT - 3740392 3 .1989 TGGTCTGGTCC - 3858102 3 .1989 TGTAACAGGAC - 3867810 3 .1989 TTCAGGTGGTT - 4008880 3 .1989 TTGGCTGCCCA - 4103765 2 .1326 AAAACAGTGGC - 4842 2 .1326 AAAGCAGTGCT - 37608 2 .1326 AAGAGGCAAGA - 141577 2 .1326 AAGCAACAGGT - 147756 2 .1326 AAGGTCGAGCT - 177704 Table 12 , cont. 2 .1326 ACAGAACTCTT - 295392 2 .1326 ACCTTGGAAGG - 391691 2 .1326 ACTCTTTGTTT - 491456 2 .1326 ACTGGCTGGGC - 501674 2 .1326 ACTTATTATGC - 511802 2 .1326 AGAACCATTAA - 529649 2 .1326 AGACCCTCTCA - 546677 2 .1326 AGCAATTCAAA - 593729 2 .1326 ATCAACACCGC - 853082 2 .1326 ATCCGAAAGAT - 876580 2 .1326 CACCACCACAG - 1131795 2 .1326 CACCTTGGTGC - 1146554 2 .1326 CACGGGACCAC - 1157202 2 .1326 CACTGACCTCC - 1171830 2 .1326 CATTATGGGTG - 1298095 2 .1326 CCCAATGGCCC - 1379990 2 .1326 CCCGGACTTAC - 1417714 2 .1326 CCCGTAGCCCC - 1421910 2 .1326 CCTACAGTTGA - 1512185 2 .1326 CCTCGGAAAAT - 1533956 2 .1326 CCTGTGTGAAA - 1555329 2 .1326 CGCCTGCTAGC - 1669578 2 .1326 CGCTGGTTCCA - 1698773 2 .1326 CGGTTCCACCC - 1766678 2 .1326 CTAATAAAGCC - 1847334 2 .1326 CTACCAGGATA - 1856141 2 .1326 CTGCTATCCGA - 1995609 2 .1326 CTGCTTTGTGC - 1998778 2 .1326 CTGGGCGTGTC - 2008814 2 .1326 CTGTAGGTGAT - 2018020 2 .1326 CTGTGCCCTCC - 2024822 2 .1326 CTTAAGGATCC - 2034230 2 .1326 GAATCTGAAGT - 2153996 2 .1326 GAATGCAGGGA - 2155689 2 .1326 GAGGAGAAGAA - 2263073 2 .1326 GATGCATAGTG - 2331439 2 .1326 GATGTGACCAC - 2340946 2 .1326 GATTTCTGTCT - 2357176 2 .1326 GCACCGAACAC - 2381842 2 .1326 GCATACGGCGC - 2410138 2 .1326 GCATTGCATCT - 2423096 2 .1326 GCCAAGGGTCA - 2427573 2 .1326 GCCAAGTGGAG - 2427811 2 .1326 GCCTAATGTAC - 2474930 2 .1326 GCCTCGGGGGA - 2480809 2 .1326 GCGACGCGGGC - 2496938 2 .1326 GCGGCGGGATG - 2529935 2 .1326 GCTCAGGATTC - 2574910 2 .1326 GCTGGCAGACG - 2598023 2 .1326 GCTTGCTTCCT - 2615256 2 .1326 GGAAGGTGTCT - 2632632 2 .1326 GGA I 1 I GGCTT - 2686624 Table 12 , cont. 2 .1326 GGGAGCTGTGC - 2762682 2 .1326 GGGGAAATCGC - 2785498 2 .1326 GGGGCTCAGCC - 2792742 2 .1326 GGTGAGCCTGA - 2853241 2 .1326 GGTGGGACACA - 2861125 2 .1326 GTAAGCATAAA - 2892993 2 .1326 GTCTGGGGGGA - 3009193 2 .1326 GTGGTAGGCTA - 3060381 2 .1326 GTTGCTGAGAA - 3120673 2 .1326 GTTGGGGGGGG - 3123883 2 .1326 TAACTGACAAT - 3176516 2 .1326 TATACAATACA - 3346629 2 .1326 TCCACTGTGCA - 3481317 2 .1326 TCTGGACGCGG - 3645851 2 .1326 TGAAACACTGT - 3671164 2 .1326 TGACCCCGGGT - 3691948 2 .1326 TGCCTGTGATA - 3767181 2 .1326 TGGATCCTGAG - 3814883 2 .132& TGGGCAAAGCC - 3837990 2 .1326 TGGTGACAAAA - 3858689 2 .1326 TGTGCCAAGTG - 3904559 2 .1326 TGTTCATCTTG - 3920767 2 .1326 TTCAGCTCGAG - 4007779 2 .1326 TTGCTGCAGTG - 4094255 Tags included in this report = 161 Table 12 , cont. DataBase Link Database = c: 16 1.061 % GGCTTCGGTCT 2750136 Noted Tags = 0 Collected Tags = 13 .862 % AGAGCGAAGTG 563247 Noted Tags = 1 Collected Tags = 1 GCGGAA, Class A, U93862, Mus musculus ribosomal protein L41 mRNA, complete 12 .7957 % AGCAGTCCCCT - 601432 Noted Tags = 4 Collected Tags = 0 12 .7957 % GTGGCTCACAA - 3054865 Noted Tags = 207 Collected Tags = 56 CCATCC, Class A, AB0046, Mus musculus mRNA for Rab33B, complete cds. CCATCT, Class C, L29190, Mouse MHC class I H2-D transplantation antigen gen CCATCT, Class A, U20225, Mus musculus adenylosuccinate lyase (adl) mRNA, co CCATCT, Class A, X93168, M.musculus mRNA for cannabinoid receptor 2. CCATCT, Class A, X56974, M.musculus mRNA for external transcribed spacer (p CCATCT, Class C, X52915, M. musculus gene for H-2D(q) antigen, partial 3' c CCATCT, Class C, V00751, Mouse gene H-2Ld coding for a transplantation anti CCATCT, Class C, X52916, M. musculus H-2L(q) gene for H-2L(q) antigen. 3" p CCATCT, Class C, U06244, Mus musculus interferon alpha/beta receptor (IFNAR CCATCC, Class C, X64716, M.musculus NKR-P1 2 gene for natural killer cell r 10 .6631 % AGGCAGACAGT - 673868 Noted Tags = 2 Collected Tags = 2 TGCTGT, Class A, X13661 , Mouse mRNA for elongation factor 1 -alpha (EF 1-alp TGCTGT, Class A, M22432, Mus musculus protein synthesis elongation factor T 9 .5968 % GCTGGCCCTTC 2598270 Noted Tags = 0 Collected Tags = 0 8 .5305 % AGGTCGGGTGG - 711355 Noted Tags = 1 Collected Tags = 0 8 .5305 % CGCCGCCGGCT 1664424 Noted Tags = 1 Collected Tags = 0 7 .4641 % CTGCTCAGGCT 1995944 Noted Tags = 1 Collected Tags = 1 TAGGAG, Class A, M13806, Mouse keratin (epidermal) type I mRNA, clone pkScc 7 .4641 % TGGGCATCCAC - 3838802 Noted Tags = 0 Collected Tags = 0 6 .3978 % AAGGAAATGGG 164075 Noted Tags = 0 Collected Tags = 0 6 .3978 % ATACTGACATT 817232 Table 12 , cont . Noted Tags = 4 Collected Tags = 0 6 .3978 % CCTTTGTGACT - 1571720 Noted Tags = 0 Collected Tags = 0 6 .3978 % GAACATTGCAC - 21 17522 Noted Tags = 3 Collected Tags = 2 CACACG, Class A, X12697, Mouse p2-4 mRNA for SPARC/osteonectin (SPARC = sec CACACG, Class C, M20691 , Mouse osteonectin (Sparc) gene, exon 9. 6 .3978 % GGGAAGGCGGC - 2755178 Noted Tags = 2 Collected Tags = 1 ACGTCT, Class A, M88335, M.musculus mRNA sequence. 5 .3315 % ATGACTGATAG - 925235 Noted Tags = 4 Collected Tags = 0 5 .3315 % CACAAACGGTA - 1114541 Noted Tags = 0 Collected Tags = 0 5 .3315 % CACCACCGTTG - 1131967 Noted Tags = 1 Collected Tags = 1 CCTTCA, Class C, M21460, Mouse surfeit locus surfeit 3 protein gene, exon 6 5 .3315 % CAGAACCCACG - 1180999 Noted Tags = 2 Collected Tags = 2 ACAGTA, Class C, M76762, Mus musculus ribosomal protein (Ke-3) gene, exons ACAGTA, Class A, M76763, Mus musculus ribosomal protein (Ke-3) mRNA, comple 5 .3315 % CCCTGAGTCCA - 1434325 Noted Tags = 2 Collected Tags = 2 CCCCGG, Class A, X03672, Mouse cytoskeletal mRNA for beta-actin. CCCCGG, Class A, J04181, Mouse A-X actin mRNA, complete cds. 5 .3315 % CCCTGGGTTCT - 1436408 Noted Tags = 2 Collected Tags = 1 GCCCGC, Class A, J04716, Mouse ferritin light chain, complete cds. 5 .3315 % GCCCGGGAATA - 2451981 Noted Tags = 1 Collected Tags = 1 AATTCA, Class A, J05277, Mouse hexokinase mRNA, complete cds. 5 .3315 % GCGGCGGATGG - 2529851 Noted Tags = 6 Collected Tags = 5 AGACTT, Class C, A27894, Coding sequence for GBP. AGACTT, Class A, X53067, Mouse mRNA for 14KDa lectin. AGACTT, Class A, X15986, Mouse 3' mRNA for beta-galactoside specific lectin AGACTT, Class A, X66532, M.musculus mRNA for L14 lectin. AGACTT, Class A, M57470, Murine beta-galactoside binding protein mRNA, comp 5 .3315 % GGAAGCCACTT - 2630944 Noted Tags = 0 Collected Tags = 0 Table 12, cont. 5 .3315% TAAAGAGGCCG -3154583 Noted Tags = 1 Collected Tags = 1 TTTTGT, Class A, U67770, Mus musculus ribosomal protein S26 (RPS26) mRNA, c 5 .3315% TATGTCAAGCT -3388456 Noted Tags = 1 Collected Tags = 1 GGTGGA, Class A, X15962, Mouse mRNA for ribosomal protein S12. 5 .3315% TGGGTTGTCTA -3849949 Noted Tags = 1 Collected Tags = 1 AAAATA, Class A, X06407, Mouse mRNA for 21 kd polypeptide under translation 5 .3315% TGTAGTGTAAT -3878596 Noted Tags = 1 Collected Tags = 1 AAAGGT, Class A, X73829, M.musculus mRNA for ribosomal protein S8. 5 .3315% TTCAGTGGACC -4009606 Noted Tags = 0 Collected Tags = 0 5 .3315% TTGGTGAAGGA -4110377 Noted Tags = 2 Collected Tags = 0 4 .2652% AGAAACCAATA -525581 Noted Tags = 2 Collected Tags = 1 CGAACA, Class A, V00830, Mouse mRNA encoding epidermal keratin subunit. 4 .2652% AGTGAGGAAGA -756233 Noted Tags = 1 Collected Tags = 0 4 .2652% ATAATACATAA -799025 Noted Tags = 4 Collected Tags = 0 4 .2652% ATACTGAAGCC -817190 Noted Tags = 1 Collected Tags = 1 CCACTT, Class A, U28917, Mus musculus 60S ribosomal protein (A52) mRNA, com 4 .2652% ATTCTCCAGTG -1013039 Noted Tags = 1 Collected Tags = 0 4 .2652% CAAACTCTCAC -1056210 Noted Tags = 2 Collected Tags = 2 AGCGAT, Class A, X04017, Mouse mRNA for cysteine-rich glycoprotein SPARC. AGCGAT, Class C, M20692, Mouse osteonectin (Sparc) gene, exon 10. 4 .2652%, CAGTCACCAAC -1233218 Noted Tags = 0 Collected Tags = 0 4 .2652% CCCACAAGGTA -1380525 Noted Tags = 0 Collected Tags = 0 4 .2652% CCTTGCTCAAT -1566532 Table 12 , cont. Noted Tags = 2 Collected Tags = 1 TAAAA , Class A, M59470, Mouse cystatin C mRNA, complete cds. 4 .2652 % CCTTTGAGATC - 1570958 Noted Tags = 1 Collected Tags = 1 ATCCAC, Class A, U78085, Mus musculus ribosomal protein S5 mRNA, complete c 4 .2652 % CTAGTCTTTGT - 1882108 Noted Tags = 1 Collected Tags = 1 ACACAA, Class A, L31609, Mus musculus (clone mcori-1ck9) S29 ribosomal prot 4 .2652 % CTGAACATCTC - 1967326 Noted Tags = 1 Collected Tags = 1 CCCCTT, Class A, X15267, Mouse mRNA for acidic ribosomal phosophoprotein PO 4 .2652 % GGCAAGCCCCA - 2689365 Noted Tags = 2 Collected Tags = 1 GCGTCT, Class A, U12403, Mus musculus Csa-19 mRNA, complete cds. 4 .26523% GGCCTGGCTTA -2718333 Noted Tags = 0 Collected Tags = 0 4 .2652 % TCCCCGTACAT - 3496724 Noted Tags = 0 Collected Tags = 0 4 .2652 % TCCCTATTAAG - 3503043 Noted Tags = 0 Collected Tags = 0 4 .2652 % TCTTCTCACAA -3661073 Noted Tags = 0 Collected Tags = 0 4 .2652 % TGGCCCAAATT - 3822608 Noted Tags = 2 Collected Tags = 1 TATGCC, Class C, M11409, Mouse S16 ribosomal protein processed pseudogene. 3 .1 AAGGTGGAAGA - 178697 Noted Tags = 0 Collected Tags = 0 3 .1989 % ACATCATAGAT - 316196 Noted Tags = 1 Collected Tags = 1 GACATC, Class A, L04280, Mus musculus ribosomal protein (Rpl12) mRNA, compl 3 .1989 % AGGAAGGCGGC - 658026 Noted Tags = 0 Collected Tags = 0 3 .1989 % CAAGTGGAAAA - 1096193 Noted Tags = 0 Collected Tags = 0 3 .1989 % CACGCTCCCGG - 1154395 Noted Tags = 0 Collected Tags = 0 3 .1989 % CAGGCCACACA - 1217605 Table 12 , cont . Noted Tags = 1 Collected Tags = 1 AGAGCC, Class A, AF0305, Mus musculus ATP synthase beta-subunit (beta-F1 AT 3 .1989 % CCAGAACAGAC - 1343778 Noted Tags = 3 Collected Tags = 0 3 .1989 % CCCAG AGCACT - 1385032 Noted Tags = 1 Collected Tags = 1 GGGTTG, Class A, M10937, Mouse epidermal 67-kDa type II keratin mRNA. 3 .1989 % CCCTAAACTGA - 1425529 Noted Tags = 0 Collected Tags = 0 3 .1989 % CCTGATCTTTA - 1543677 Noted Tags = 2 Collected Tags = 2 CTTCTA, Class A, X06406, Mouse mRNA for translational controlled 40 kDa pol CTTCTA, Class A, J02870, Mouse laminin receptor mRNA, complete cds. 3 .1989 % CCTTTAATCCC - 1568982 Noted Tags = 58 Collected Tags = 9 AGCACT, Class A, D42051 , Mus musculus mRNA for Glutamate Decarboxylase, com AGAGGC, Class A, X79508, M.musculus (C57BIJ10) CW37 mRNA, B1 repeat. AGCACT, Class A, U03421 , Mus musculus interieukin-11 mRNA, complete cds. AGTTAC, Class C, U59807, Mus musculus cystatin B (Stfb) gene, complete cds. AGCACT, Class A, M58288, Mus musculus granulocyte colony-stimulating factor AGCACC, Class C, M14361 , Mouse Ig germline kappa-chain V-region gene V-Ser, AGCAAT, Class C, M93320, Mus musculus DNA fragment, L1 repeat family region AGCCCT, Class C, J00632, mouse b1 ubiquitous repeat (copy c) mrna and flank AGGACT, Class A, L08394, Mus musculus betacellutin (ben) mRNA, complete cds 3 .1989 % CTCAACAGCAA - 1901713 Noted Tags = 0 Collected Tags = 0 3 .1989 % CTCCTGGACAC - 1931794 Noted Tags = 1 Collected Tags = 1 CTGGGA, Class A, J04953, Mouse gelsolin gene, complete cds. 3 .1989 % CTGGCTTTCAG - 2006995 Noted Tags = 0 Collected Tags = 0 3 .1989 % GACTTTGGAAA - 2227841 Noted Tags = 6 Collected Tags = 3 ACATTT, Class A, U03419, Mus musculus alpha-1 type I procollagen mRNA, part ACATTT, Class C, X57981 , Mouse gene for pro alphal (I) collagen chain (COL1 ACATTT, Class A, U08020, Mus musculus FVB/N collagen pro-alpha-1 type I cha 3 .1989 % GAGCGTTTTGG - 2256891 Noted Tags = 2 Collected Tags = 1 GTCCAG, Class A, X52803, Mouse mRNA for cyclophilin (EC 5.2.1.8). 3 .1989 % GATGACACCAG - 2327635 Noted Tags = 1 Collected Tags = 1 Table 12 , cont. CCGCTC, Class A, U11248, Mus musculus C57BIJ6J ribosomal protein S28 mRNA, 3 .1989 % GCTGCAGTTGA 2593529 Noted Tags = 0 Collected Tags = 0 3 .1989 % GCTGCCCTCCA 2594261 Noted Tags = 5 Collected Tags = 0 3 .1 GTCTGCTGATG - 3008399 Noted Tags = 2 Collected Tags = 2 GCCAGA, Class A, X75313, M.musculus (C57BIJ6) GB-like mRNA. GCCAGA, Class A, D29802, Mouse mRNA for G protein beta subunit homologue, c 3 .1 GTGGAGGCGCC - 3050086 Noted Tags = 0 Collected Tags = 0 3 .1989 % GTGGGCGTGTA - 3057389 Noted Tags = 1 Collected Tags = 1 CAACGG, Class A, JΛ33330, Mouse insulinoma (rig) mRNA, complete cds. 3 .1989 % TAAACCTGCTA -3151773 Noted Tags = 0 Collected Tags = 0 3 .1989 % TATCCCACGCC - 3363942 Noted Tags = 0 Collected Tags = 0 3 .1989 % TCGGTTTCTGC - 3587962 Noted Tags = 0 Collected Tags = 0 3 .1989 % TCTCACCACCC -3622166 Noted Tags = 0 Collected Tags = 0 3 .1989 % TGACCCCGGGA -3691945 Noted Tags = 0 Collected Tags = 0 3 .1989 % TGCACAGTGCT - 3740392 Noted Tags = 5 Collected Tags = 4 GAGCAA, Class A, X05835, Mouse mRNA for placental calcium-binding protein. GAGCAA, Class A, X16190, Mouse mtsl gene. GAGCAA, Class A, Z36947, Murine retrovirus RNA containing parts of mtsl of GAGCAA, Class A, D00208, Mus musculus mRNA for pEL98 protein, complete cds. 3 .1 TGGTCTGGTCC - 3858102 Noted Tags = 0 Collected Tags = 0 3 .1989 % TGTAACAGGAC 3867810 Noted Tags = 1 Collected Tags = 1 TGCTAT, Class A, X04648, Mouse mRNA for lgG1/lgG2b Fc receptor (FcR). 3 .1989 % TTCAGGTGGTT - 4008880 Noted Tags = 1 Collected Tags = 1 TCTTCT, Class A, X73607, M.musculus mRNA for tropomyosin 5 (3'UTR). Table 12 , cont . 3 .1989 % TTGGCTGCCCA - 4103765 Noted Tags = 1 Collected Tags = 1 GGATGT, Class C, Y08307, M.musculus mitochondrial mRNA for ribosomal protei 2 .1326 % AAAACAGTGGC - 4842 Noted Tags = 1 Collected Tags = 1 CGGTGG, Class A, X73331 , M.musculus mRNA for ribosomal protein L37a. 2 .1326 % AAAGCAGTGCT - 37608 Noted Tags = 0 Collected Tags = 0 2 .1326 % AAGAGGCAAGA - 141577 Noted Tags = 0 Collected Tags = 0 2 .1326 % AAGCAACAGGT - 147756 Noted Tags = 0 Collected Tags = 0 2 .1326 % AAGGTCGAGCT - 177704 Noted Tags = 0 Collected Tags = 0 2 .1326 % ACAGAACTCTT - 295392 Noted Tags = 1 Collected Tags = 1 CTCAAT, Class A, AJ002 us musculus mRNA for annexin VIII. 2 .1326 % ACCTTGGAAGG - 391691 Noted Tags = 1 Collected Tags = 0 2 .1326 % ACTCTTTGTTT - 491456 Noted Tags = 0 Collected Tags = 0 2 .1326 % ACTGGCTGGGC - 501674 Noted Tags = 0 Collected Tags = 0 2 .1326 % ACTTATTATGC - 511802 Noted Tags = 0 Collected Tags = 0 2 .1326 % AGAACCATTAA - 529649 Noted Tags = 0 Collected Tags = 0 2 .1326 % AGACCCTCTCA - 546677 Noted Tags = 0 Collected Tags = 0 2 .1 AGCAATTCAAA 593729 Noted Tags = 6 Collected Tags = 2 CAATTA, Class C, U09637, Mus musculus domesticus mitochondrion NADH dehydro CAATTA, Class C, U09638, Mus musculus musculus mitochondrion NADH dehydroge 2 .1326 % ATCAACACCGC - 853082 Noted Tags = 2 Collected Tags = 2 AACCTT, Class A, Y00703, Mouse uncoupled S49 cells mRNA for stimulatory GTP AACCTT, Class A, M13964, Mouse stimulatory G protein of adenylate cyclase, Table 12, cont. 2 .1326 % ATCCGAAAGAT - 876580 Noted Tags = 2 Collected Tags = 1 GAAGCT, Class A, L04128, Mus musculus ribosomal protein L18 (rpL18) mRNA, c 2 .1326 % CACCACCACAG - 1131795 Noted Tags = 1 Collected Tags = 1 GATCAA, Class A, X05021 , Murine mRNA with homology to yeast L29 ribosomal p 2 .1326 % CACCTTGGTGC 1146554 Noted Tags = 0 Collected Tags = 0 2 .1326 % CACGGGACCAC - 1 157202 Noted Tags = 0 Collected Tags = 0 2 .1326 % CACTGACCTCC - 1 171830 Noted Tags = 1 Collected Tags = 0 2 .1326 /ό CATTATGGGTG - 1298095 Noted Tags = 3 Collected Tags = 3 GCAAGA, Class A, U16818, Mus musculus UDP glucuronosyltransferase (UGT1-06) GCAAGA, Class A, ' L02333, Murine bilirubin/phenol family UDP glucuronosyltra GCAAGA, Class A, L27122, Mus musculus (A-1) bilirubin/phenol UDP-glucuronos 2 .1326 % CCCAATGGCCC - 1379990 Noted Tags = 3 Collected Tags = 3 AATAAA, Class A, X65582, M.musculus mRNA for alpha-2 collagen VI. AATAAA, Class A, X62332, M.musculus mRNA for alpha-2 collagen type VI, subu AATAAA, Class A, Z18272, Mus musculus collagen alpha 2 chain type VI. 2 .1326 % CCCGGACTTAC - 1417714 Noted Tags = 2 Collected Tags = 0 2 .1326 % CCCGTAGCCCC - 1421910 Noted Tags = 1 Collected Tags = 1 TTCCGA, Class A, M22479, Mouse tropomyosin isoform 2 mRNA, complete cds. 2 .1326 % CCTACAGTTGA - 1512185 Noted Tags = 3 Collected Tags = 3 TAATCT, Class C, K02241 , Mouse alkali myosin light chains, exons 6 and 7 co TAATCT, Class A, K02242, Mouse alkali myosin light chains MLC1f and MLC3f 3 TAATCT, Class C, K02243, Mouse alkali myosin light chains MLC1f/MLC3f pseud 2 .1326 % CCTCGGAAAAT - 1533956 Noted Tags = 0 Collected Tags - 0 2 .1326 % CCTGTGTGAAA 1555329 Noted Tags = 0 Collected Tags = 0 2 .1326 % CGCCTGCTAGC 1669578 Noted Tags = 2 Collected Tags = 1 CAACCG, Class A, X58251 , Mouse COL1A2 mRNA for pro-alpha-2(l) collagen. Table 12 , cont. 2 .1326 % CGCTGGTTCCA - 1698773 Noted Tags = 2 Collected Tags = 0 2 .1326 % CGGTTCCACCC - 1766678 Noted Tags = 0 Collected Tags = 0 2 .1326 % CTAATAAAGCC - 1847334 Noted Tags = 3 Collected Tags = 2 ACTGTG, Class A, X65922, M.musculus fau mRNA. ACTGTG, Class A, D26610, Mouse mRNA for monoclonal nonspecific suppressor f 2 CTACCAGGATA 1856141 Noted Tags Collected Tags = 0 2 .1326 % CTGCTATCCGA 1995609 Noted Tags = 1 Collected Tags = 1 GAGAAT, Class A, X83590, M.musculus mRNA for ribosomal protein L5, 3'end. 2 .1326 % CTGCTTTGTGC - 1998778 Noted Tags = 2 Collected Tags = 2 TGTACA, Class A, M13227, Mouse enkephalin mRNA. TGTACA, Class A, M55181 , Mouse spermatogenic-specific proenkephalin mRNA, c 2 .1326 % CTGGGCGTGTC - 2008814 Noted Tags = 0 Collected Tags = 0 2 .1326 % CTGTAGGTGAT - 2018020 Noted Tags = 0 Collected Tags = 0 2 .1326 % CTGTGCCCTCC - 2024822 Noted Tags = 0 Collected Tags = 0 2 .1326 % CTTAAGGATCC - 2034230 Noted Tags = 0 Collected Tags = 0 2 .1326 % GAATCTGAAGT -2153996 Noted Tags = 0 Collected Tags = 0 2 .1326 % GAATGCAGGGA -2155689 Noted Tags = 0 Collected Tags = 0 2 .1326 % GAGGAGAAGAA - 2263073 Noted Tags = 2 Collected Tags = 1 AGCATT, Class A, Y00225, Murine mRNA for J1 protein, yeast ribosomal protei 2 .1326 % GATGCATAGTG - 2331439 Noted Tags = 1 Collected Tags = 0 2 .1326 % GATGTGACCAC 2340946 Noted Tags = 0 Collected Tags = 0 Table 12 , cont . 2 .1326 % GATTTCTGTCT - 2357176 Noted Tags = 0 Collected Tags = 0 2 .1326 % GCACCGAACAC - 2381842 Noted Tags = 0 Collected Tags = 0 2 .1326 % GCATACGGCGC - 2410138 Noted Tags = 1 Collected Tags = 0 2 .1326 % GCATTGCATCT - 2423096 Noted Tags = 0 Collected Tags = o 2 .1326 % GCCAAGGGTCA - 2427573 Noted Tags = 1 Collected Tags = 1 GAGGCT, Class A, L08651 , Mus musculus large ribosomal subunit protein mRNA, 2 .1326 % GCCAAGTGGAG - 2427811 Noted Tags = 5 Collected Tags = 1 TTCCCA, Class A. M76131 , Mouse elongation factor 2 (ef-2) mRNA, 3' end. 2 .1326 % GCCTAATGTAC - 2474930 Noted Tags = 1 Collected Tags = 1 ACAAAG, Class A, U93863, Mus musculus ribosomal protein L21 mRNA, complete 2 .1326 % GCCTCGGGGGA - 2480809 Noted Tags = 0 Collected Tags = 0 2 .1326 % GCGACGCGGGC - 2496938 Noted Tags = 0 Collected Tags = 0 2 .1326 % GCGGCGGGATG - 2529935 Noted Tags = 0 Collected Tags = 0 2 .1326 % GCTCAGGATTC -2574910 Noted Tags = 1 Collected Tags = 1 ATCTGA, Class A, X91824, M.musculus mRNA for SPRRIa protein. 2 .1 GCTGGCAGACG - 2598023 Noted Tags = 0 Collected Tags = 0 2 .1326 % GCTTGCTTCCT - 2615256 Noted Tags = 1 Collected Tags = 1 GGAGCA, Class A, X89650, M.musculus mRNA for Rab7 protein. 2 .1326 % GGAAGGTGTCT - 2632632 Noted Tags = 0 Collected Tags = 0 2 .1326 % GGATTTGGCTT - 2686624 Noted Tags = 0 Collected Tags = 0 2 .1326 % GGGAGCTGTGC - 2762682 Noted Tags = 0 Collected Tags = 0 Table 12 , cont. 2 .1326 % GGGGAAATCGC - 2785498 Noted Tags = 1 Collected Tags = 1 CAGCTT, Class A, Z48496, M.musculus mRNA for testis-specific thymosin beta- 2 .1326 % GGGGCTCAGCC 2792742 Noted Tags = 2 Collected Tags = 0 2 .1326 % GGTGAGCCTGA 2853241 Noted Tags = 1 Collected Tags = 1 AGCTTG, Class A, U20611 , Mus musculus thioredoxin-dependent peroxide reduct 2 .1326 % GGTGGGACACA - 2861125 Noted Tags = 0 Collected Tags = 0 2 .1326 % GTAAGCATAAA - 2892993 Noted Tags = 0 Collected Tags = 0 2 .1326 % GTCTGGGGGGA - 3009193 Noted Tags = 0 Collected Tags = 0 2 .1326 % GTGGTAGGCTA - 3060381 Noted Tags = 0 Collected Tags = 0 2 .1326 % GTTGCTGAGAA - 3120673 Noted Tags = 2 Collected Tags = 2 GCGGCT, Class A, X75312, M.musculus (C57BU6) QM mRNA. GCGGCT, Class A, M93980, Mouse 24.6 kda protein mRNA, complete cds. 2 .1326 % GTTGGGGGGGG - 3123883 Noted Tags = 0 Collected Tags = 0 2 .1326 % TAACTGACAAT - 3176516 Noted Tags = 1 Collected Tags = 0 2 .1326 % TATACAATACA 3346629 Noted Tags = 0 Collected Tags = 0 2 .1326 % TCCACTGTGCA 3481317 Noted Tags = 1 Collected Tags = 1 CGTGTG, Class C, L38580, Mus musculus galanin gene, exon 6 and complete cds 2 .1326 % TCTGGACGCGG - 3645851 Noted Tags = 2 Collected Tags = 2 AAAGCA, Class C, M33988, Mouse histone H2A.1 gene, complete cds. CAAGCA, Class C, M37736, Mouse replication-dependent histone H2A.1 gene. 2 .1326 % TGAAACACTGT - 3671164 Noted Tags = 2 Collected Tags = 2 , Class A, D86344, Mouse mRNA for Topoisomerase-inhibitor suppressed, T , Class A, D50465, Mouse MA-3 (apoptosis-related gene) mRNA, complete Table 12, cont. 2 .1326 % TGACCCCGGGT 3691948 Noted Tags = 0 Collected Tags = 0 2 .1326 % TGCCTGTGATA - 3767181 Noted Tags = 0 Collected Tags = 0 2 .1326 % TGGATCCTGAG - 3814883 Noted Tags = 21 Collected Tags = 4 AACTTC, Class C, V00742, Fragment of the mouse gene for epsilon-globin Y3 ( AACTTC, Class A, M19236, Mouse beta-globin gene. AACTTC, Class C, J00414, Mouse beta-globin epsilon y3 gene, exon 2. AACTTC, Class C, M 10688, Mouse beta-globin gene with intron boundary. 2 .1326 % TGGGCAAAGCC - 3837990 Noted Tags = 0 Collected Tags = 0 2 .1326 % TGGTGACAAAA - 3858689 Noted Tags = 0 Collected Tags = 0 2 .1326?% TGTGCCAAGTG - 3904559 Noted Tags = 0 Collected Tags = 0 2 .1326 % TGTTCATCTTG 3920767 Noted Tags = 2 Collected Tags = 1 TTTTAA, Class C, X57983, Mouse gene for pro alphal (III) collagen chain (CO 2 .1326 % TTCAGCTCGAG - 4007779 Noted Tags = 0 Collected Tags = 0 2 .1326 % TTGCTGCAGTG 4094255 Noted Tags = 0 Collected Tags = 0 Table 13 SAGE Analysis of MRL Mice Five Days After Wounding SearchName = C5BANK FileName = c:\sage\data\c5data\c5bank.bag Anchoring Enzyme = Nlalll - CATG Tag Length = 11 DiTag Length = 24 Total Files = 67 Total Tags = 1790 Total Duplicate Dimers = 0 Tag Abundance Report Total tags after excluding tags = 1790 Count PerceTj^i Tag Sequence -Tag BaseFour Number 23 1.28*9 CGGTCCAGGGA - 1758377 18 1.0Q55 GTGGCTCACAA - 3054865 16 .8938 GGCTTCGGTCT - 2750136 14 .7821 AGGTCGGGTGG - 711355 13 .7262 CACAAACGGTA - 1114541 13 .7262 TGGGTTGTCTA - 3849949 12 .6703 CGCCGCCGGCT - 1664424 12 .6703 CTGCTCAGGCT - 1995944 12 .6703 GCTGGCCCTTC - 2598270 11 .6145 AGGCAGACAGT - 673868 11 .6145 TTGGCTGCCCA - 4103765 10 .5586 GCCCGGGAATA - 2451981 9 .5027 AGAGCGAAGTG - 563247 9 .5027 CAGAACCCACG - 1180999 9 .5027 CATCGCCAGTG - 1271087 9 .5027 CCCCAGCCAGT - 1395020 8 .4469 AGCAGTCCCCT - 601432 8 .4469 CAAACTCTCAC - 1056210 8 .4469 CTAATAAAGCC - 1847334 8 .4469 GGCAAGCCCCA - 2689365 7 .391 CAAGGTGACAG - 1093139 7 .391 CCAGAACAGAC - 1343778 7 .391 CTGAACATCTC - 1967326 7 .391 GCCTTTATGAG - 2489571 7 .391 GGAAGCCACTT - 2630944 7 .391 GTGAACGTGCC - 3016422 7 .391 GTGGGCGTGTA - 3057389 6 .3351 AACACCAAGCT - 70696 6 .3351 CACCACCACAG - 1131795 6 .3351 CACCACCGTTG - 1131967 6 .3351 CACGCTCCCGG - 1154395 6 .3351 CCCGTGTGCTC - 1424286 6 .3351 CCTTGCTCAAT - 1566532 Table 13, cont. 6 .3351 CTGCTATCCGA - 1995609 6 .3351 GAACATTGCAC - 2117522 6 .3351 GGATTTGGCTT - 2686624 6 .3351 GGGAAGGCGGC - 2755178 6 .3351 GTCTGCTGATG - 3008399 6 .3351 TCAGGCTGCCT - 3450776 6 .3351 TGGATCCTGAG - 3814883 5 .2793 CGCTGGTTCCA - 1698773 5 .2793 CTCCTGGACAC - 1931794 5 .2793 TATGTCAAGCT - 3388456 5 .2793 TCGTGATTGTG - 3597295 5 .2793 TTCAGTGGACC - 4009606 4 .2234 AAGAGGCAAGA - 141577 4 .2234 ATACTGACATT - 817232 4 .2234 CAAGTGGAAAA - 1096193 4 .2234 CCCAATGGCCC - 1379990 4 .2234 CCTACCAAGAC - 1512482 4 .2234 GATGACACCAG - 2327635 4 .2234 GATTCCGTGAG - 2348771 4 .2234 GCAGAGTGCGC - 2395034 4 .2234 GCCAAGTGGAG - 2427811 4 .2234 GCGGCGGATGG - 2529851 4 .2234 GTGGAGGCGCC - 3050086 4 .2234 TGCACAGTGCT - 3740392 4 .2234 TGGATCAGTCT - 3814584 4 .2234 TGGCTCGGTCA - 3831477 4 .2234 TGTGCCAAGTG - 3904559 4 .2234 1 l ul l IGGTGA - 4062905 3 .1675 AGTGAGGAAGA - 756233 3 .1675 CACCTTGGTGC - 1146554 3 .1675 CCCTGAGTCCA - 1434325 3 .1675 CTACCACTCAA - 1855953 3 .1675 CTGAGAGAGAA - 1974817 3 .1675 CTGTAGACTGC - 2017402 3 .1675 CTGTAGGTGAT - 2018020 3 .1675 CTTGACACACA - 2065477 3 .1675 GAGTCTCCCTG - 2284895 3 .1675 GATGTGGCTGC - 2341498 3 .1675 GCCGCTAGGCC - 2464934 3 .1675 GCCTGTGGCCT • 2485912 3 .1675 GCGCCCTCCCC - 2512726 3 .1675 GGGGGCCCAGG - 2794827 3 .1675 GTGTGGGCACT - 3074632 3 .1675 GTGTTAACCAG - 3076179 3 .1675 TAAAGAGGCCG - 3154583 3 .1675 TGCTTATGATG - 3797903 3 .1675 TGGTGACAAAA • 3858689 3 .1675 TGTCAGTCTGT - 3885948 3 .1675 TTCAGCTCGAG - 4007779 2 .1117 AACAATTTGGG - 69611 2 .11 17 AACAGGTTCAA - 76753 2 .1117 AAGCGCCTCAC - 157138 Table 13 , cont . 2 .1117 AAGGAAATGGG - 164075 2 .1117 AAGGTCTGCCT - 178072 2 .1117 AAGGTGGAAGA - 178697 2 .1117 ACAGTTCCAGA - 310601 2 .1117 ACCCTCCTCCC - 357846 2 .1117 AGAGGAAGCTG - 565407 2 .1117 AGCAGGGATCC - 600630 2 .1117 AGGAAGGCGGC - 658026 2 .1117 AGGGAGCGCTA - 690589 2 .1117 AGTGACTCTGG - 755579 2 .1117 ATTCTCCAGTG - 1013039 2 .1117 ATTTGATTAGC - 1041354 2 .1117 Ai Π TCCAGTG - 1045807 2 .1117 CAATGTGGGTT - 1109680 2 .1117 CACAGACTGTG - 1122799 2 .1117 CACAGCCCACT - 1123656 2 .1117 CACCGCCAGTG - 1140015 2 .1117. CACGGCTTTCA - 1157109 2 .1117- CACGGGACCAC - 1157202 2 .1117 s CAGTCACCAAC - 1233218 2 .1117 CAGTCTCTCAA - 1236433 2 .1117 CCAACGCTTTA - 1317373 2 .1117 CCACCTCCTGT - 1334652 2 .1117 CCCAGGCTGAA - 1386977 2 .1117 CCCTAAACTGA - 1425529 2 .1117 CCCTCTACAAG - 1432643 2 .1117 CCCTGGGTTCT - 1436408 2 .1117 CCCTGTGGCCG - 1437335 2 .1117 cccTTCTTcτc - 1439710 2 .1117 CCGCCTGCAAG - 1465923 2 .1117 CCTCAGCCTGG - 1526139 2 .1117 CCTCGCACAGT - 1533004 2 .1117 CCTTTAATCCC - 1568982 2 .1117 CCTTTGTGACT - 1571720 2 .1117 CGCCTGCTAGC - 1669578 2 .1117 CTGAGAGAAAA - 1974785 2 .1117 CTGCCTCACAG - 1989907 2 .1117 CTGCGAGATTC - 1991230 2 .1117 CTGCTTTGTGC - 1998778 2 .1117 CTGTCTGAAAG - 2022915 2 .1117 CTTCTCATTTG - 2061567 2 .1117 CTTGCTCAATG - 2071823 2 .1117 CTTGGCGAGCG - 2074151 2 .1117 GAAAGTTGGCC - 2109350 2 .1117 GAACGCGACGG - 2123291 2 .1117 GACTTTGGAAA - 2227841 2 .1117 GAGTTTTCACG - 2293575 2 .1117 GCACAACTTGC - 2376186 2 .11 17 GCACTGCGCAC - 2390418 2 .1117 GCCCCCGCATA - 2446925 2 .11 17 GCCCCTGCGCA - 2448997 2 .1117 GCCTAATGTAC - 2474930 Table 13 , cont . .1117 GCCTCCTCCCA - 2479957 .1117 GCCTTGGTGAA - 2489057 .1117 GCGAAGCTCAG - 2492883 .1117 GCGGCGCCGCA - 2529637 .1117 GCTCTCCAGCA - 2585893 .1117 GCTGCCCTCCA - 2594261 .1117 GCTGTGGCCAC - 2603602 .1117 GGCAGCCCCCT - 2696536 .1117 GGCTGGGGGCT - 2747048 .1117 GGGCCTGTGGG - 2776811 .1117 GGTGCCAACTA - 2855965 .1117 GGTGGGGGGGC - 2861738 .1117 GTCACAGGCAA - 2953873 .1117 GTCTGCGTGCC - 3008230 .1117 GTCTGGGGGGA - 3009193 .1117 GTCTGTGCCCA - 3010133 .1117 GTGAGCCCATT - 3024208 .1117 GTGGCGCACGC - 3053850 .1117 GTGGCTCACAG - 3054867 .1117 GTGGGTGTTGG - 3059451 .1117 TATCTGTGCAT - 3373972 .1117 TATTGGCTCTG - 3402207 .1117 TCACTGGCCCC - 3439190 .1117 TCCAACTCCTT - 3475296 .1117 TCCCTGTGGTT - 3505072 .1117 TCCGGGCGAGG - 3516811 .1117 TCTCACCACCC - 3622166 .1117 TCTGCCAATTT - 3642432 .1117 TCTGGACGCGG - 3645851 .1117 TCTTCTCACAA - 3661073 .1117 TGAACCGTCCC - 3675862 .1117 TGACAGCTGCC - 3688934 .1117 TGACCCCGGGC - 3691946 .1117 TGACCCCGGGT - 3691948 .1117 TGAGCATCGGG - 3707755 .1117 TGCGTGCTGGA - 3783145 .1117 TGGCCCAAATT - 3822608 .111.7 TGTAACAGGAC - 3867810 .1117 TGTAACTGGTC - 3868590 2 .1117 TGTGAACTTTG - 3899903 2 .1117 TGTTCATCTTG - 3920767 2 .1117 TTCAGCTCGAA - 4007777 2 .1117 TTCTGTCCTGT - 4058492 2 .1117 TTGCACCTTCT - 4081144 2 .1117 TTGGGCCAGAG - 4105507 2 .1117 TTGGTGAAGGA - 4110377 2 .1117 TTTCGTGTTGG - 4157179 2 .1117 1 1 1 1 CCACTTG - 4183167 Tags included in this report = 185 Table 13 , cont. DataBase Link Database = c: 23 1.2849 % CGGTCCAGGGA - 1758377 Noted Tags = 0 Collected Tags = 0 18 1.0055 % GTGGCTCACAA 3054865 Noted Tags = 207 Collected Tags = 56 CCATCC, Class A, AB0046, Mus musculus mRNA for Rab33B, complete cds. CCATCT, Class C, L29190, Mouse MHC class I H2-D transplantation antigen gen CCATCT, Class A, U20225, Mus musculus adenylosuccinate lyase (adl) mRNA, co CCATCT, Class A, X93168, M.musculus mRNA for cannabinoid receptor 2. CCATCT, Class A, X56974, M.musculus mRNA for external transcribed spacer (p CCATGT, Class C, X52915, M. musculus gene for H-2D(q) antigen, partial 3' c CCATGT, Class C, V00751, Mouse gene H-2Ld coding for a transplantation anti CCATCT, Class C, X52916, M. musculus H-2L(q) gene for H-2L(q) antigen. 3' p CCATCT, Class C, UQ6244, Mus musculus interferon alpha beta receptor (IFNAR CCATCC, Class C, X6^16, M.musculus NKR-P1 2 gene for natural killer cell r 16 93β % GGCTTCGGTCT - 2750136 Noted Tags Collected Tags = 0 14 .7821 % AGGTCGGGTGG 711355 Noted Tags = 1 Collected Tags = 0 13 .7262 % CACAAACGGTA 1114541 Noted Tags = 0 Collected Tags = 0 13 .7262 % TGGGTTGTCTA - 3849949 Noted Tags = 1 Collected Tags = 1 AAAATA, Class A, X06407, Mouse mRNA for 21 kd polypeptide under translation 12 .6703 % CGCCGCCGGCT - 1664424 Noted Tags = 1 Collected Tags = 0 12 .6703 % CTGCTCAGGCT - 1995944 Noted Tags = 1 Collected Tags = 1 TAGGAG, Class A, M13806. Mouse keratin (epidermal) type I mRNA, clone pkScc 12 .6703 % GCTGGCCCTTC - 2598270 Noted Tags = 0 Collected Tags = 0 11 .6145 % AGGCAGACAGT - 673868 Noted Tags = 2 Collected Tags = 2 TGCTGT, Class A, X13661. Mouse mRNA for elongation factor 1 -alpha (EF 1-alp TGCTGT, Class A, M22432. Mus musculus protein synthesis elongation factor T 11 .6145 % TTGGCTGCCCA - 4103765 Noted Tags = 1 Collected Tags = 1 GGATGT, Class C, Y08307. M.musculus mitochondrial mRNA for ribosomal protei Table 13 , cont. 10 .5586 % GCCCGGGAATA - 2451981 Noted Tags = 1 Collected Tags = 1 AATTCA, Class A, J05277, Mouse hexokinase mRNA, complete cds. 9 .5027 % AGAGCGAAGTG - 563247 Noted Tags = 1 Collected Tags = 1 GCGGAA, Class A, U93862, Mus musculus ribosomal protein L41 mRNA, complete 9 .5027 % CAGAACCCACG - 1180999 Noted Tags = 2 Collected Tags = 2 ACAGTA, Class C, M76762, Mus musculus ribosomal protein (Ke-3) gene, exons ACAGTA, Class A, M76763, Mus musculus ribosomal protein (Ke-3) mRNA, comple .5027 % CATCGCCAGTG - 1271087 Nc d Tags = 3 Collected Tags = 2 GGCAAA, Class A, M12414, Mouse apolipoprotein E mRNA, complete cds. "GGCAAA, Class A, M73490, Mus musculus apolipoprotein E mRNA, 3' end. 9 .5027 % CCCCAGCCAGT - 1395020 Noted Tags = 2 Collected Tags = 1 GCCTAC, Class A, X76772, M.musculus mRNA for ribosomal protein S3. 8 .4469 % AGCAGTCCCCT - 601432 Noted Tags = 4 Collected Tags = 0 8 .4469 % CAAACTCTCAC - 1056210 Noted Tags = 2 Collected Tags = 2 AGCGAT, Class A, X04017, Mouse mRNA for cysteine-rich glycoprotein SPARC. AGCGAT, Class C, M20692, Mouse osteonectin (Sparc) gene, exon 10. 8 .4469 % CTAATAAAGCC - 1847334 Noted Tags = 3 Collected Tags = 2 ACTGTG, Class A, X65922, M.musculus fau mRNA. ACTGTG, Class A, D26610, Mouse mRNA for monoclonal nonspecific suppressor f 8 .4469 % GGCAAGCCCCA - 2689365 Noted Tags = 2 Collected Tags = 1 GCGTCT, Class A, U12403, Mus musculus Csa-19 mRNA, complete cds. 7 .391 % CAAGGTGACAG - 1093139 Noted Tags = 3 Collected Tags = 3 GCCGCT, Class A, M20632, Mouse LLRep3 protein mRNA from a repetitive elemen GCCGCT, Class C, M20633, Mouse LLRep3 protein pseudogene from a repetitive GCCGCT, Class C, M20634, Mouse LLRep3 protein pseudogene from a repetitive 7 .391 % CCAGAACAGAC - 1343778 Noted Tags = 3 Collected Tags = 0 7 .391 % CTGAACATCTC - 1967326 Noted Tags = 1 Collected Tags = 1 CCCCTT, Class A, X15267, Mouse mRNA for acidic ribosomal phosophoprotein PO Table 13 , cont . 7 .391 % GCCTTTATGAG - 2489571 Noted Tags = 2 Collected Tags = 1 AAGAAA, Class A, X60289, M.musculus mRNA for ribosomal protein S24. 7 .391 % GGAAGCCACTT - 2630944 Noted Tags = 0 Collected Tags = 0 7 .391 % GTGAACGTGCC - 3016422 Noted Tags = 0 Collected Tags = 0 7 .391 % GTGGGCGTGTA - 3057389 Noted Tags = 1 Collected Tags = 1 CAACGG, Class A, M33330, Mouse insulinoma (rig) mRNA, complete cds. 6 .3351 % AACACCAAGCT - 70696 Noted Tags = 2 Goliected Tags = 2 GTCCCT, Class A, X74784, M.musculus mk2e mRNA. GTCCCT, Class A, M24.1.51 , Mouse keratin 70 kd type II mRNA, 3' end. 6 .335T*7o CACCACCACAG - 1131795 Noted Tags = 1 , Collected Tags = 1 GATCAA, Class A, X05021 , Murine mRNA with homology to yeast L29 ribosomal p 6 .3351 % CACCACCGTTG - 1131967 Noted Tags = 1 Collected Tags = 1 CCTTCA, Class C, M21460, Mouse surfeit locus surfeit 3 protein gene, exon 6 6 .3351 % CACGCTCCCGG - 1154395 Noted Tags = 0 Collected Tags = 0 6 .3351 % CCCGTGTGCTC - 1424286 Noted Tags = 0 Collected Tags = 0 6 .3351 % CCTTGCTCAAT - 1566532 Noted Tags = 2 Collected Tags = 1 TAAAA , Class A, M59470, Mouse cystatin C mRNA, complete cds. 6 .3351 % CTGCTATCCGA - 1995609 Noted Tags = 1 Collected Tags = 1 GAGAAT, Class A, X83590, M.musculus mRNA for ribosomal protein L5, 3'end. 6 .3351 % GAACATTGCAC - 2117522 Noted tags = 3 Collected Tags = 2 CACACG, Class A, X12697. Mouse p2-4 mRNA for SPARC/osteonectin (SPARC = sec CACACG, Class C, M20691, Mouse osteonectin (Sparc) gene, exon 9. 6 .3351 % GGATTTGGCTT - 2686624 Noted Tags = 0 Collected Tags = 0 6 .3351 % GGGAAGGCGGC - 2755178 Noted Tags = 2 Collected Tags = 1 ACGTCT, Class A, M88335, M.musculus mRNA sequence. n Table 13 , cont . 6 .3351 % GTCTGCTGATG - 3008399 Noted Tags = 2 Collected Tags = 2 GCCAGA, Class A, X75313, M.musculus (C57BU6) GB-like mRNA. GCCAGA, Class A, D29802, Mouse mRNA for G protein beta subunit homologue, c 6 .3351 % TCAGGCTGCCT - 3450776 Noted Tags = 7 Collected Tags = 6 TCATCT, Class A, X12812, Murine mRNA for macrophage ferritin heavy subunit. TCATCT. Class C, X52561 , Mouse gene for ferritin H subunit. TCATCT, Class A, J03941 , Mouse ferritin heavy chain (MFH) mRNA, complete cd TTATCT, Class A, M24509, Mouse ferritin heavy chain, complete cds. TTATCC, Class C, M73678, Mus musculus (clone pMHFY9) ferritin H pseudogene. TTATCT, Class C, M73679, Mus musculus (clone pMHFYI) ferritin H pseudogene. 6 .3351 % TGGATCCTGAG - 3814883 Noted Tags = 21 Collected Tags = 4 AACTTC, Class C, V00742, Fragment of the mouse gene for epsilon-globin Y3 ( AACTTC, Class A, M19236, Mouse beta-globin gene. AACTTC, Class C, J00414, Mouse beta-globin epsilon y3 gene, exon 2. AACTTC, Class C, M10688, Mouse beta-globin gene with intron boundary. 5 .2793 % CGCTGGTTCCA 1698773 Noted Tags = 2 Collected Tags = 0 5 .2793 % CTCCTGGACAC - 1931794 Noted Tags = 1 Collected Tags = 1 CTGGGA, Class A, J04953, Mouse gelsolin gene, complete cds. 5 .2793 % TATGTCAAGCT - 3388456 Noted Tags = 1 Collected Tags = 1 GGTGGA, Class A, X15962, Mouse mRNA for ribosomal protein S12. 5 .2793 % TCGTGATTGTG - 3597295 Noted Tags = 3 Collected Tags = 3 CAGAAT, Class A, U52822, Mus musculus ornithine decarboxylase anti∑yme mRNA CAGAAT, Class C, U52823, Mus musculus ornithine decarboxylase antizyme gene CAGAAT, Class C, U84291, Mus musculus ornithine decarboxylase antizyme gene 5 .2793 % TTCAGTGGACC - 4009606 Noted Tags = 0 Collected Tags = 0 4 .2234 % AAGAGGCAAGA - 141577 Noted Tags = 0 Collected Tags = 0 4 .2234 % ATACTGACATT - 817232 Noted Tags = 4 Collected Tags = 0 4 .2234 % CAAGTGGAAAA - 1096193 Noted Tags = 0 Collected Tags = 0 4 .2234 % CCCAATGGCCC - 1379990 99/41364 Table 13 , cont . Noted Tags = 3 Collected Tags = 3 AATAAA, Class A, X65582, M.musculus mRNA for alpha-2 collagen VI. AATAAA, Class A, X62332, M.musculus mRNA for alpha-2 collagen type VI, subu AATAAA, Class A, Z18272, Mus musculus collagen alpha 2 chain type VI. 4 .2234 % CCTACCAAGAC - 1512482 Noted Tags = 0 Collected Tags = 0 4 .2234 % GATGACACCAG - 2327635 Noted Tags = 1 Collected Tags = 1 CCGCTC, Class A, U11248, Mus musculus C57BL/6J ribosomal protein S28 mRNA, 4 .2234 % GATTCCGTGAG - 2348771 Noted Tags = 0 Collected Tags = 0 4 ,2234 % GCAGAGTGCGC - 2395034 Noted Tags = 2 Collected Tags = 1 CTGCTG, Class A, Y00348, Mouse mRNA for ribosomal protein S6. 4 .2234*% GCCAAGTGGAG - 2427811 Noted Tags = 5 Collected Tags = 1 TTCCCA, Class A, M76131, Mouse elongation factor 2 (ef-2) mRNA, 3' end. 4 .2234 % GCGGCGGATGG - 2529851 Noted Tags = 6 Collected Tags = 5 AGACTT, Class C, A27894, Coding sequence for GBP. AGACTT, Class A, X53067, Mouse mRNA for 14KDa lectin. AGACTT, Class A, X15986, Mouse 3' mRNA for beta-galactoside specific lectin AGACTT, Class A, X66532, M.musculus mRNA for L1 lectin. AGACTT, Class A, M57470, Murine beta-galactoside binding protein mRNA, comp 4 .2234 % GTGGAGGCGCC - 3050086 Noted Tags = 0 Collected Tags = 0 4 .2234 % TGCACAGTGCT - 3740392 Noted Tags = 5 Collected Tags = 4 GAGCAA, Class A, X05835, Mouse mRNA for placenta! calcium-binding protein. GAGCAA, Class A, X16190, Mouse mtsl gene. GAGCAA, Class A, Z36947, Murine retrovirus RNA containing parts of mtsl of GAGCAA, Class A, D00208, Mus musculus mRNA for pEI_98 protein, complete cds. 4 .2234 % TGGATCAGTCT - 3814584 Noted Tags = 1 Collected Tags = 1 TTAAAA, Class A, M62952, Mus musculus ribosomal protein L19, complete cds. 4 .2234 % TGGCTCGGTCA - 3831477 Noted Tags = 6 Collected Tags = 3 CTTGGG, Class A, X13055, Murine mRNA for cytoplasmic gamma-actin. CTTGGG, Class C, X13056, Murine gamma-118-actin pseudogene. CTTGGG, Class A, M21495, Mouse cytoskeletal gamma-actin mRNA, complete cds. 4 .2234 % TGTGCCAAGTG - 3904559 Table 13 , cont . Noted Tags = 0 Collected Tags = 0 4 .2234 % TTCTTTGGTGA 4062905 Noted Tags = 1 Collected Tags = 0 3 .1675 % AGTGAGGAAGA 756233 Noted Tags = 1 Collected Tags = 0 3 .1675 % CACCTTGGTGC 1146554 Noted Tags = 0 Collected Tags = 0 3 .1675 % CCCTGAGTCCA 1434325 Noted Tags = 2 Collected Tags = 2 CCCCGG, Class A, X03672, Mouse cytoskeletal mRNA for beta-actin. CCCCGG, Class A, J04181, Mouse A-X actin mRNA, complete cds. 3 .1675 % CTACCACTCAA - 1855953 Noted Tags = 0 Collected Tags = 0 3 .1675 % CTGAGAGAGAA - 1974817 Noted Tags = 0 Collected Tags = 0 3 .1675 % CTGTAGACTGC - 2017402 Noted Tags = 0 Collected Tags = 0 3 .1675 % CTGTAGGTGAT - 2018020 Noted Tags = 0 Collected Tags = 0 3 .1675 % CTTGACACACA - 2065477 Noted Tags = 0 Collected Tags = 0 3 .1675 % GAGTCTCCCTG - 2284895 Noted Tags = 2 Collected Tags = 2 GATTGT, Class C, X59747, Mouse Sm B gene for Sm B protein of U snRNP's, exo GATTGT, Class A, M58761 , Mouse Sm-B protein gene, complete cds. 3 .1675 % GATGTGGCTGC - 2341498 Noted Tags = 0 Collected Tags = 0 3 .1675 % GCCGCTAGGCC - 2464934 Noted Tags = 0 Collected Tags = 0 3 .1675 % GCCTGTGGCCT -2485912 Noted Tags = 0 Collected Tags = 0 3 .1675 % GCGCCCTCCCC -2512726 Noted Tags = 1 Collected Tags = 1 TTGTCC ciass A, U88322, Mus musculus beta chemokine Exodus-2 mRNA, comptet 3 .1675 % GGGGGCCCAGG - 2794827 Noted Tags = 1 Collected Tags = 1 TGTAGA, Class C, X03059, Mouse germline gene for T-cell receptor J-alpha 65 99/41364 Table 13 , cont . 3 .1675 % GTGTGGGCACT - 3074632 Noted Tags = 1 Collected Tags = 1 GGATTT, Class A, X93035, M.musculus mRNA for BRP39 protein. 3 .1675 GTGTTAACCAG - 3076179 Noted Tags = 0 Collected Tags = 0 3 .1675 % TAAAGAGGCCG - 3154583 Noted Tags = 1 Collected Tags = 1 TTTTGT, Class A, U67770, Mus musculus ribosomal protein S26 (RPS26) mRNA, c 3 .1675 % TGCTTATGATG 3797903 Noted Tags = 0 Collected Tags = 0 3 .1675 % TGGTGACAAAA - 3858689 Noted Tags = 0 Collected Tags = 0 3 .1675J& TGTCAGTCTGT 3885948 Noted Tags = 1 Collected Tags = 1 TTAACC, Class C, M21050, Mouse lysozyme M gene, exon 4. 3 .1675 % TTCAGCTCGAG - 4007779 Noted Tags = 0 Collected Tags = 0 2 .1117 % AACAATTTGGG - 69611 Noted Tags = 0 Collected Tags = 0 2 .1117 % AACAGGTTCAA - 76753 Noted Tags = 0 Collected Tags = 0 2 .1117 % AAGCGCCTCAC - 157138 Noted Tags = 0 Collected Tags = 0 2 .1117 % AAGGAAATGGG - 164075 Noted Tags = 0 Collected Tags = 0 2 .1117 % AAGGTCTGCCT - 178072 Noted Tags = 1 Collected Tags = 1 GAAAAC, Class A, D87896, Mus musculus phgpx mRNA for phospholipid hydropero 2 .1117 % AAGGTGGAAGA - 178697 Noted Tags = 0 Collected Tags = 0 2 .1117 % ACAGTTCCAG A 310601 Noted Tags = 3 Collected Tags = 3 AGTGAT, Class A, AF0234, Mus musculus HS1 -associating protein (mHAX-1s) mRN AGTGAT, Class A, AF0234, Mus musculus HS-1 -associating protein HAX-1L (mHAX AGTGAT, Class A, X81444, M.musculus SIG-111 mRNA. 2 .1117 % ACCCTCCTCCC 357846 Noted Tags = 3 Collected Tags = 2 Table 13, cont. CCCGCT. Class C, K01365, Mouse 18S-5.8S-28S rRNA gene internal transcribed CCCGCT. Class C, J00623. Mouse 18S, 5.8S, 28S rRNA gene cluster (clone pMEB 2 .1117% AGAGGAAGCTG -565407 Noted Tags = 0 Collected Tags = 0 2 .1 17% AGCAGGGATCC -600630 Noted Tags = 1 Collected Tags = 1 CCGTGC, Class A, X97490, M.musculus mRNA for PNG protein. 2 .1117% AGGAAGGCGGC -658026 Noted Tags = 0 Collected Tags = 0 2 .1117% Table 14 O Accession Numbers for Wound Healing Genes I υ Ei- 0 Table 14, cont. 00 Table 14, cont. co O Table 15, cont. Table 16 Segregation of Quantitative Trait Loci in Phenotype Congenic Mice Table 16, cont. REFERENCES 1. Gross, J. Getting to mammalian wound repair and amphibian limb regeneration: a mechanistic link in the early events. Wound Repair and Regeneration 4,190-202, 1996. 2. Stocum, D.L. Tissue restoration: approaches and prospects. Wound Repair and Regeneration. 4, 3-15, 1996. 3. Borgens, R.B. Mice regrow the tips of the foretoes. Science 217,747-50, 1982. 4. Goss,R.J. Problems of antlerogenesis. Clin. Orthopaedics 69,227-38, 1970. 5. Goss, R. J. and Grimes, L.N. Epidermal downgrowths in regenerating rabbit ear holes. J. Morphology 146, 533-42, 1975. 6. Fausto, N. Hepatic regeneration. In Hepatology: a textbook in liver disease, 2nd edition (eds. Zakim, D. and Boyer ,T.D.), pp. 49-65 Saunders, Philadelphia, 1990. 7. Michalopoulos, G.K. and DeFrances, M.C. Liver Regeneration. Science 276, 60-66, 1997. 8. Folkman, J. and Klagsbrun, M. Angiogenic factors. Science 235, 442-447,1987. 9. Potten, C.S. and Morris, R.J. Epithelial stem cells in vivo. In Stem Cells. (eds. Lord, B.I. and Dexter, T.M.) pp. 45-62, The Company of Biologists Limited, Cambridge, 1988. 10. Martin, P. Wound Healing - Aiming for perfect skin regeneration. Science 276, 75-81, 1997. 11. Spangrude,G.J., Heimfeld, S., Weisman I.L. Purification and characterization of mouse hematopoietic stem cells. Science 241, 58-62, 1988. 12. Wornom, I.L. and Buchman, S.R. Bone and cartilaginous tissue. In Wound healing: biochemical and clinical aspects., (eds. Cohen, I.K., Diegelmann, R.F. and Lindblad, W.J.) pp.356-83, Saunders, Philadelphia, 1992. 13. Murphy, E.D. and Roths, J.B. Autoimmunity and lymphoproliferation: Induction by mutant gene lpr and acceleration by a male-associated factor in strain BXSB. TrtGenetic Control of Autoimmune Disease., (eds. Rose, N.R., Bigazzi, P.E., and Warner, N.L).pp. 207-220, Elsevier, New York, 1979. 14. Cohen, P.L. and Eisenberg, R.A. Lpr and gld: Single Gene models of Systemic Autoimmunity and Lymphoproliferartive disease. Annu. Rev. Immunol. 9,243-69, 1991. 15. Theofilopoulos, A.N. Immunologic genes in mouse lupus models. In The Molecular Pathology of Autoimmune Diseases, (eds. Bona, C, Siminovitch, K.A., Zanetti, M. and Theofilopoulos, A.N.) pp. 281-316, Harwood Academic Publishers, Langhorne, 1993. 16. Watanabe-Fukunaga, R., Brannan, C, Copeland, N.G., Jenkins, N.A. and Nagata, S. Lymphoproliferation disorder in mice is explained by defects in Fas antigen that mediates apoptosis. Nature 356, 314-316, 1992. 17. Watson, M.L., et. al. Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene to disease manifestations and renal disease modifying loci. J. Exp. Med. 176, 1645-1656, 1992. 18. Russell, P.S. and Billingham, R.E. Some aspects of the repair process in mammals. Prog. Surg. 2,1-72, 1962. 19. Chalkley, D.T. The cellular basis of limb regeneration. In Regeneration in vertebrates, (ed. Thornton, C.S.) pp.34-58, Univ. of Chicago Press, Chicago, 1959. 20. Simon, H-G, Kittappa, R., Khan, P.A., Tsilfιdis,C, Liversage, R.A., and Oppenheimer, S. A novel family of T-box genes in urodele amphibian limb development and regeneration: candidate genes in vertebrate forelimb/hindlimb patterning. Development 124:1355-1366,1997. 21. Muneoka, K., Fox,W.F., and Bryant, S.V. Cellular contribution from dermis and cartilage to the regenerating limb blastema in axolotls. Developmental Biology 116: 256-60, 1986. 22. Carrel, A. and Hartmann, A. Cicatrization of wounds. I. The relation between the size of the wound and the rate of its cicatrization. J.Exp. Med. 24: 429-450, 1916. 23. Adachi, M., Watanabe-Fukunaga, R. and Nagata, S. Aberrant transcription caused by the insertion of an endogenous retrovirus in an apoptosis gene. PNAS 90,1756-1760,1993. 24. Costa, O. and Monier, J.C. Anithistone antibodies detected by microELISA and immunoblotting in mice with lupus-like syndrome (MRL/1, MRL/n, PN, AND NZB strains). Clin. Immunol. Immunopath. 40, 276-282,1986. 25. Clark, R.A.F. Wound Repair: Overview and general considerations. In The Molecular and Cellular Biology of Wound Repair. (ed.Clark, R.) pp. 3-35, Plenum Press, New York, 1996. 26. Yamada, K.M. and Clark, R.A.F. Provisional Matrix In The Molecular and Cellular Biology of Wound Repair. (ed.Clark, R.) pp.51-82, Plenum Press, New York, 1996. 27. Stocum, D.L. The urodele limb regeneration blastema. Determination and organization of the morphogenetic field. Differentiation. 27,13-28, 1984. 28. Mustoe, T.A., Pierce, G.F., Morishima, C. and Deuel, T.F. Growth factor-induced acceleration of tissue repair through direct and inductive activities in a rabbit dermal ulcer model. J. Clin. Invest. 87, 694-703, 1991. 29. Pierce, G.F., et. al. Platelet-derived growth factor (BB homodimer), transforming growth factor-Bl, and basic fibroblast growth factor in dermal wound healing: Neovessel and matrix formation and cessation of repair. Am. J. Pathol. 140, 1375-1388, 1992. 30. Uhl, E., et al. Basic fibroblast growth factor accelerates wound healing in chronically ischaemic tissue. Br. J. Surg. 80, 977-980, 1993. 31. McBrearty, B.A., Desquenne Clark, L., Zhang, X-M, Blankenhorn, E.P., and Heber-Katz,E. Genetic analysis of a mammalian wound healing trait. Proc. Natl. Acad. Sci. U.S.A., in press. 32. Ragsdale, C.W., Gates, P., Hill, D. S. and Brockes, J.P. Delta retinoic acid receptor isoform dl is distinquished by its exceptional N-terminal sequence and abundance in the limb regeneration blastema. Mechanisms of Development. 40,99-112, 1992. 33. White, J. A., Boffa, M. B., Jones, B. and Petkovich, M. A zebrafish retinoic acid expressed in the regenerating caudal fin. Development. 120, 1861-1872, 1994. 34. Chernoff, E.A.G. and Stocum, D. Developmental aspects of spinal cord and limb regeneration. Dev. Growth Diff 37,133-47, 1995. 35. Joseph, J., and Dyson, M. (1966) Brit. J. Surg. 53, 372-380. 36. Clark,L.D., Clark, R.K., and Heber-Katz, E. (1998) Clin Immunol Immunopath, 88, 34-45. 37. Murphy E.D. (1981) in Immunological defects in laboratory animals Vol.2, eds. Gershwin, M.E., Merchant, B. (New York and London), pp 143-73. 38. Dietrich, W. F. et al. (1994) Nαtwre Genetics 1, 220-245. 39. Manly, K. F. (1993) Mammalian Genome 4, 303-313. 40. Doerge, R.W., and Churchill, G.A. (1996) Genetics 142, 285-294. 41. Churchill, G.A., and Doerge, R.W. (1994) Genetics 138, 963-971. 42. Wright, S. in Quantitative Genetics (1952) eds. Reeve, E. C. and Waddington, C. H.) (HMSO, London), pp. 5-41 . 43. Hartl, D. L. in Basic Genetics (1991) (Jones and Bartlett, Boston), pp. 218-220. 44. Lander, E.S., and Krugylak, L. (1995). Nature Genetics 11, 241-247. 45. Cheveraud, J.M., and Routman, E.J. (1995) Genetics 139, 1455-61. 46. FrankeLW. (1995) Trends Genet 11, 471-477. 47. Simon, MI, Strathmann, MP, and Gautum, Ν. (1991) Science 252, 802-808. 48. Bryant, S.V. and Gardinar, D.M. (1997J in Metamorphosis and regeneration: Keys to tissue Regeneration, p. 12. 49. Reginelli, A.D., Wang,Y-Q, Sassoon, D., and Muneoka, K. (1995) Development 121, 1065-1076. 50. Chuong, CM., Widelitz, R.B., Ting-Berreth, S., and Jiang., T.X. (1996) J. Invest. Derm. 107, 639-646. 51. Ron, D., Reich,R., Chedid, M., Lengel, C, Cohen, O.E., Chan, A.M. Νeufeld, G., Miki, T., and Tronick, S.R. (1993) J. Biol.Chem. 268, 5388-5394. 52. Percrino, L. T., Lo, D. C, Brockes, J. P. (1994) Development 20, 325-333. 53. Sucov, H. M. and Evans, R. M. (1995) Molecular Neurobiology 10, 1969-184. 54. Shah, M., et /. (1995) J. Cell Sci. 108, 15-17.

Claims: CLAIMS 1. A method of identifying a gene involved in enhanced wound healing, comprising the steps of: identifying DNA microsatellite markers which can distinguish a first and a second mouse strain, wherein the first mouse strain is a healer mouse strain and wherein the second mouse strain is not a healer mouse strain; and identifying microsatellite markers which segregate with enhanced wound healing in progeny of the first and second mouse strains, whereby a chromosomal locus which contains at least one gene involved in enhanced wound healing is identified. 2. The method of claim 1 wherein the first mouse strain is an MRL mouse. 3. The method of claim 1 wherein the first mouse strain is a progeny of a healer mouse and a non-healer mouse. 4. The method of claim 3 wherein the healer mouse is an MRL mouse. 5. The method of claim 1 wherein the first mouse strain is created by: performing a cross between a first mouse of a healer strain and a mouse of a non-healer strain to form an F, mouse; and performing a back-cross between the F, mouse and a second mouse of the healer strain. 6. The method of claim 1 wherein the first mouse strain is created by: performing a cross between a mouse of a healer strain and a first mouse of a non-healer strain to form an F, mouse; and performing a back-cross between the F, mouse and a second mouse of the non-healer strain. 7. The method of claim 1 wherein the first mouse strain is created by: performing a cross between a mouse of a healer strain and a mouse of a non-healer strain to form F, progeny mice; and performing a cross between two of the F, progeny mice to form F 2 progeny mice. 8. The method of claim 1 wherein the first mouse strain is created by successive repetition of the steps of claim 5. 9. The method of claim 1 wherein the first mouse strain is created by successive repetition of the steps of claim 6. 10. The method of claim 1 wherein the first mouse strain is a progeny of a first non-healer mouse and a second non-healer mouse. 11. The method of claim 1 wherein the first mouse strain comprises at least one quantitative trait locus selected from the group consisting of the quantitative trait loci shown in Tables 2 , 9, and 16, wherein the first mouse exhibits an enhanced healing response to a wound compared to a second mouse which does not comprise the at least one chromosomal locus, wherein the first mouse is not an MRL mouse. 12. A method of treating a wound in a mammal, comprising the step of: administering to a mammal with a wound a reagent which specifically binds to an expression product of a gene whose expression is decreased after wounding in a healer mouse relative to expression of the gene after wounding in a non-healer mouse, whereby expression of the gene is decreased. 13. The method of claim 12 wherein the gene is selected from the group consisting of genes of Tables 5-8, 10, 11, 14, 15, and genes comprising a SAGE tag of Tables 12 and 13 whose expression is decreased after wounding. 14. The method of claim 12 wherein the gene is selected from the group consisting of msx2 and RARg. 15. The method of claim 12 wherein the expression product is an mRNA. 16. The method of claim 15 wherein the reagent is an antisense oligonucleotide. 17. The method of claim 12 wherein the expression product is a protein. 18. The method of claim 17 wherein the reagent is an antibody. 19. The method of claim 12 wherein the wound is contacted with the reagent. 20. The method of claim 12 further comprising the step of suppressing T cell function in the mammal. 21. A method of treating a wound in a mammal, comprising the step of: administering to a mammal with a wound an expression product of a gene whose expression is increased after wounding in a healer mouse relative to expression of the gene after wounding in a non-healer mouse, whereby the level of the expression product in the wound is increased. 22. The method of claim 21 wherein the gene is selected from the group consisting of genes of Tables 5-8, 10, 11, 14, 15, and genes comprising a SAGE tag of Tables 12 and 13 whose expression is increased after wounding. 23. The method of claim 21 wherein the gene is selected from the group consisting of msx2 and RARg. 24. The method of claim 21 wherein the expression product is provided using a Polynucleotide which encodes the expression product. 25. The method of claim 21 wherein the wound is contacted with the expression product. 26. The method of claim 21 further comprising the step of suppressing T cell function in the mammal. 27. A method of restoring function after nerve injury in a mammal, comprising the step of: administering to a mammal with a nerve injury a reagent which specifically binds to an expression product of a gene whose expression is decreased after wounding in a healer mouse relative to expression of the gene after wounding in a non-healer mouse, whereby expression of the gene is decreased. 28. The method of claim 27 wherein the expression product is an mRNA. 29. The method of claim 28 wherein the reagent is an antisense oligonucleotide. 30. The method of claim 27 wherein the expression product is a protein. 31. The method of claim 30 wherein the reagent is an antibody. 32. The method of claim 27 wherein the gene is selected from the group consisting of genes of Tables 5-8, 10, 11, 14, 15, and genes comprising a SAGE tag of Tables 12 and 13 whose expression is decreased after wounding. 33. The method of claim 27 wherein the gene is selected from the group consisting of msx2 and RARg. 34. The method of claim 27 further comprising the step of suppressing T cell function in the mammal. 35. The method of claim 27 wherein the nerve injury is contacted with the expression product. 36. A method of restoring function after nerve injury in a mammal, comprising the step of: administering to a mammal with a nerve injury an expression product of a gene whose expression is increased after wounding in a healer mouse relative to expression of the gene after wounding in a non-healer mouse, whereby the level of the expression product in the wound is increased. 37. The method of claim 36 wherein the gene is selected from the group consisting of genes of Tables 5-8, 10, 11, 14, 15, and genes comprising a SAGE tag of Tables 12 and 13 whose expression is increased after wounding. 38. The method of claim 36 wherein the gene is selected from the group consisting of msx2 and RARg. 39. The method of claim 36 further comprising the step of suppressing T cell function in the mammal. 40. The method of claim 36 wherein the nerve injury is contactedwith the expression product. 41. The method of claim 36 wherein the expression product is provided using a polynucleotide which encodes the expression product. 42. A method of treating a wound in a mammal, comprising the step of: administering to a mammal with a wound a cell or a cellular extract obtained from a healer mouse, whereby healing of the wound in the mammal is enhanced. 43. The method of claim 42 wherein the transferred cell is selected from the group consisting of macrophages, fetal liver cells, dendritic cells, stem cells, peripheral blood leukocytes, and bone marrow cells. 44. The method of claim 42 further comprising the step of suppressin g T cell function in the mammal. 45. A method of treating a wound in a mammal, comprising the step of: administering to a mammal with a wound a cell in which expression of a wound healing gene has been altered, whereby healing of the wound in the mammal is enhanced. 46. The method of claim 45 wherein the wound healing gene is selected from the group consisting of genes of Tables 5-8, 10, 11, 14, 15, and genes comprising a SAGE tag of Tables 12 and 13. 47. The method of claim 45 wherein the wound healing gene is selected from the group consisting of msx2 and RARg. 48. The method of claim 45 further comprising the step of suppressing T cell function in the mammal. 49. A healer mouse having at least one quantitative trait locus selected from the group consisting of the quantitative trait loci shown in Tables 2 , 9, and 16, wherein the healer mouse exhibits an enhanced healing response to a wound compared to a mouse which does not have the at least one chromosomal locus, wherein the healer mouse is not an MRL mouse. 50. The healer mouse of claim 49 which is created by: performing a cross between a mouse of a healer strain and a mouse of a non-healer strain. 51. The healer mouse of claim 49 which is created by: performing a cross between a mouse of a first non-healer strain and a mouse of a second non-healer strain. 52. The healer mouse of claim 49 which is created by: performing a cross between a mouse of a healer strain and a mouse of a non-healer strain to form F, progeny mice; and performing a cross between two of the F, progeny mice to form F 2 progeny mice. 53. The healer mouse of claim 49 which is created by: performing a cross between a mouse of a healer strain and a first mouse of a non-healer strain to form an F, mouse; and performing a back-cross between the F, mouse and a second mouse of the non-healer strain. 54. The healer mouse of claim 49 which is created by: performing a cross between a first mouse of a healer strain and a mouse of a non-healer strain to form an F, mouse; and performing a back-cross between the F, mouse and a second mouse of the healer strain. 55. The healer mouse of claim 49 which is created by successive repetition of the steps of claim 48. 56. The healer mouse of claim 49 which is created by successive repetition of the steps of claim 49. 57. The healer mouse of claim 49, wherein a hole punched in an ear of the healer mouse closes at least 70% within 60 days after punching. 58. The healer mouse of claim 49 wherein the enhanced healing response comprises regeneration of a wounded tissue. 59. The healer mouse of claim 49 wherein the wound is a neural tissue wound. 60. The healer mouse of claim 59 wherein the neural tissue is spinal cord. 61. The healer mouse of claim 59 wherein the neural tissue is optic nerve. 62. The healer mouse of claim 49 which is a male mouse. 63. The healer mouse of claim 49 which is a female mouse. 64. The healer mouse of claim 49 which is T cell deficient. 65. A preparation comprising a fraction of an extract of a tissue of a healer mouse, wherein the preparation alters a biological property of a model of wound healing. 66. The preparation of claim 65 wherein the biological property is selected from the group consisting of enhanced wound healing, enhanced tissue regeneration, cell growth, apoptosis, cell movement, cell adhesion, cell replication, DNA synthesis, protein synthesis, mRNA synthesis, and mRNA stability. 67. A preparation comprising cells of a healer mouse, wherein the preparation alters a biological property of a model of wound healing. 68. The preparation of claim 67 wherein the biological property is selected from the group consisting of enhanced wound healing, enhanced tissue regeneration, cell growth, apoptosis, cell movement, cell adhesion, cell replication, DNA synthesis, protein synthesis, mRNA synthesis, and mRNA stability. 69. The preparation of claim 67 wherein the cells are selected from the group consisting of macrophages, fetal liver cells, dendritic cells, stem cells, peripheral blood leukocytes, and bone marrow cells. 70. A method of identifying a factor involved in enhanced wound healing, comprising the steps of: contacting a model of wound healing with a fraction of a composition selected from the group consisting of serum, a fraction of serum, an extract of at least one healer mouse tissue, and a fraction of an extract of at least one healer mouse tissue; assaying a property of the model of wound healing, wherein a fraction of a composition which alters the property of the model of wound healing is identified as comprising a factor involved in enhanced wound healing. 71. The method of claim 70 wherein the model of wound healing is an in vitro model. 72. The method of claim 70 wherein the model of wound healing is an in vivo model. 73. The method of claim 70 wherein the property of the model of wound healing is selected from the group consisting of enhanced wound healing, enhanced tissue regeneration, cell growth, apoptosis, cell movement, cell adhesion, cell replication, DNA synthesis, protein synthesis, mRNA synthesis, and mRNA stability. 74. A method of screening test compounds for the ability to enhance wound healing, comprising the steps of: contacting a healer model of wound healing with a test compound, wherein the healer model comprises cells of a healer mouse; and measuring the effect of the test compound on a biological property associated with wound healing in the healer model, wherein a test compound which enhances the biological property of the healer model is identified as a potential factor for enhancing wound healing. 75. The method of claim 74 wherein the biological property of the healer model is selected from the group consisting of enhanced wound healing, enhanced tissue regeneration, cell growth, apoptosis, cell movement, cell adhesion, cell replication, DNA synthesis, protein synthesis, mRNA synthesis, and mRNA stability. 76. The method of claim 74 wherein the healer model is an in vitro model. 77. The method of claim 74 wherein the healer model is an in vivo model. 78. The method of claim 74 further comprising the step of comparing the effect of the test compound on the biological property of the healer model with a biological property of a non-healer model of wound healing, wherein a test compound which alters the biological property of the non-healer model to resemble the biological property of the healer model is identified as a potential factor for enhancing wound healing.

Inventors: HEBER-KATZ ELLEN, HEBER-KATZ, ELLEN
Applicants: HEBER KATZ ELLEN, WISTAR INST, HEBER-KATZ, ELLEN, THE WISTAR INSTITUTE
Application year: 1999
Main classification: C12N15
IPC codes: A01K67, A61K48, C12N5, C12N15, C12Q1, G01N33